<?xml version="1.0" encoding="utf-8"?><soap:Envelope xmlns:soap="http://schemas.xmlsoap.org/soap/envelope/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><soap:Body><Protocol_or_StudyResponse xmlns="http://www.compass.fhcrc.org/edrn_ws/ws_newcompass.asmx"><Protocol_or_StudyResult>&lt;recordNumber&gt;1&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;0&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;2&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;0&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;3&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;0&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;4&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;5&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;6&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;NYU Lung Cancer Biomarker Center&lt;/value&gt;&lt;recordNumber&gt;7&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;8&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;9&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Screen Detection of Mismatch Repair Deficient Colorectal Neoplasias Using a Stool Based DNA Analysis&lt;/value&gt;&lt;recordNumber&gt;10&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;11&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;12&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection Research Network Registry for Hereditary Cancer&lt;/value&gt;&lt;recordNumber&gt;13&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;14&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;15&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms&lt;/value&gt;&lt;recordNumber&gt;16&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1. Men 35 or older
2. Men w/o prior history of prostate cancer if no increased risk for developing prostate cancer
3. Recommended 50 years of age, if no increased risk for developing prostate cancer
4. Recommended 40 years of age if they are either African-American or have a positive family history of prostate cancer (1st or 2nd degree relative), if increase risk of developing prostate cancer
5. Willing to allow samples to be collected and entered into SABOR Biorepository
6. Able to provide informed consent&lt;/value&gt;&lt;recordNumber&gt;17&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;18&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)&lt;/value&gt;&lt;recordNumber&gt;19&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;20&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The Biomarker Development Laboratory is focused on the &amp;#060;br&amp;#062;application of a proteomic approach for the development&amp;#060;br&amp;#062; of cancer biomarkers.  The laboratory will apply &amp;#060;br&amp;#062;technologies for protein analysis to the detection and &amp;#060;br&amp;#062;identification of proteins secreted by tumor cells and &amp;#060;br&amp;#062;protein antigens that induce a humoral response in tumor&amp;#060;br&amp;#062;s.  The initial targeted tumor types for the identification&amp;#060;br&amp;#062; of potential biomarker proteins are:  Colon, esophagus,&amp;#060;br&amp;#062; ovary, lung, breast and liver.  The proposed studies will&amp;#060;br&amp;#062; make heavy utilization of two-dimensional (2-D) protein&amp;#060;br&amp;#062; analysis, of protein identification technologies and of &amp;#060;br&amp;#062;database capabilities that have been developed by the &amp;#060;br&amp;#062;applicant group.  The objectives of this research are &amp;#060;br&amp;#062;to 1.  Identify tumor antigens that induce a humoral &amp;#060;br&amp;#062;response; 2.  Identify tumor secreted proteins and develop&amp;#060;br&amp;#062;a database; 3.  Preliminarily validate the potential utility&amp;#060;br&amp;#062;of markers for early cancer detection.  Sixty ml of blood&amp;#060;br&amp;#062;will be obtained from healthy normals, and from small &amp;#060;br&amp;#062;cell lung cancer, hepatoma, esophageal, and breast cancer&amp;#060;br&amp;#062;patients, and from ovarian, colon, and non-small cell lung&amp;#060;br&amp;#062;cancer patients prior to surgical resection and six to&amp;#060;br&amp;#062;ten weeks after resection.  Demographic data, sera and &amp;#060;br&amp;#062;DNA will be used in 2-D protein analysis to identify new&amp;#060;br&amp;#062;or altered proteins.  The initial validation will be the &amp;#060;br&amp;#062;assay of the presence or absence of a given protein in a&amp;#060;br&amp;#062;large sample cohort from the samples collected from these&amp;#060;br&amp;#062;patients.  There is no specified age range, although the &amp;#060;br&amp;#062;diseases under study do not occur in children.  No subjects&amp;#060;br&amp;#062;will be excluded on the basis of race or gender.  Women&amp;#060;br&amp;#062;of child bearing age will be studied.  Linkable demographic&amp;#060;br&amp;#062;data will be held separately from the bar-coded serum or&amp;#060;br&amp;#062;DNA samples.  Serum and DNA sample will be identifiable&amp;#060;br&amp;#062;only by subject identification number.  Full written &amp;#060;br&amp;#062;informed consent will be obtained from patients.&lt;/value&gt;&lt;recordNumber&gt;21&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomics Biomarker Development Laboratory&lt;/value&gt;&lt;recordNumber&gt;22&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;23&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;24&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of the Mutagen Sensitivity and Chromosomal Hotspot Assays&lt;/value&gt;&lt;recordNumber&gt;25&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;26&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;27&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of Serum Markers of Breast Cancer by SELDI&lt;/value&gt;&lt;recordNumber&gt;28&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;29&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;30&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection of Urinary Bladder Cancer&lt;/value&gt;&lt;recordNumber&gt;31&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;32&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Major strides in the early detection, staging, monitoring, and risk stratification of men with prostate cancer have been realized over the last few decades.  We have recently witnessed a reduction in the death rate for prostate cancer, stage migration with increased numbers of men with local/regional disease, and a greater understanding of the natural history of progression following recurrence.  These advances, while not solely dependant on biomarkers, can be attributed to the discovery of Prostate Specific Antigen (PSA) in the late 1970&amp;#39;s.  In the wake of these discoveries, we still continue to unnecessarily biopsy men at risk for having prostate cancer to identify the 1:4 with the disease, understage men with presumed local disease, continue to lack an accurate method for staging which can direct treatment options for the individual patient and continue to poorly understand the tumor biology and kinetics of disease progression.  Clearly, discovery of a new tumor marker and validation/clinical investigation of the markers are mandatory to advance our knowledge and direct the care of men with prostate cancer.  With this research, we intend to evaluate the clinical, diagnostic, and prognostic accuracy of new and existing biomarkers on a prospective serum bank collected from men either participating in early detection programs or engaging in pre or post treatment situations.  By increasing our clinical research and specimen collections we hope to further advance the staging and direction for treatment in men with prostate cancer.

This study approaches patients scheduled for a prostate biopsy, patients visiting the Urology Outpatient Clinic with PSA elevation, patients scheduled for radical prostatectomy, prostate cancer patients with scheduled appointments in Radiation Oncology and men participating in early prostate cancer detection screenings. 

Subjects will be excluded from the study if:
1)  Subjects have any mental impairment that would hinder the ability to provide informed consent.
2) The subject has undergone a radical prostatectomy and is visiting the urology clinic for a follow up appointment.  We can not evaluate the protein profiles in the serum/urine for this group of patients because of prostate removal.  
3)  Subjects have had previous chemotherapy treatment.  Such treatments often induce oxidative damage that could affect protein expression. Therefore, such patients are excluded as their exposure histories may be confounded with respect to exposures relevant to prostate cancer.
4) The patient has had previous prostate surgery. These procedures will affect protein expression.
5)  Subjects have had previous cancer other than non-melanoma skin cancer.  Systemic oxidative DNA damage is suspected as a potential etiologic factor in a number of other cancers.  Therefore, such patients are excluded as their exposure histories maybe confounded with respect to exposures relevant to prostate cancer.

Upon receiving consent, urine and blood specimens are collected from the subjects.  The urine and blood are then processed and stored in our freezer bank.  This study represents little to no risk to the patient. Risks include mild pain and bruising which may result from the needle stick. There is a very small chance of infection.  There is also a very small chance that the patient may feel faint or pass out from the needle stick.  These are the usual risks associated with phlebotomy. Collection of the urine introduces no increased risk to the patient. Adverse experiences that are both serious and unexpected will be immediately reported by telephone to the Primary Investigator, Alan. W. Partin M.D., Ph.D., (410) 614-4876.
&lt;/value&gt;&lt;recordNumber&gt;33&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development and Evaluation of a Tumor Marker for Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;34&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;35&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The Biomarker Knowledge System Informatics Pilot Project goal will develop network interfaces among databases that contain information about existing clinical populations and biospecimens and data relating to those specimens that are important in biomarker assay validation.  This protocol comprises one of two that will comprise the Moffitt participation in the Biomarker Knowledge System Informatics Pilot Project.   THIS PROTOCOL (58) is the Sput-Epi Database.&lt;/value&gt;&lt;recordNumber&gt;36&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;The Biomarker Knowledge System Informatics Pilot Project Supplement To The Biomarker Development Laboratory at Moffitt (Bedlam)&lt;/value&gt;&lt;recordNumber&gt;37&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;38&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;39&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;CLUE Studies: Evaluating Biomarkers of Carcinogenesis&lt;/value&gt;&lt;recordNumber&gt;40&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;41&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;42&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Clinical Validation of Molecular Signatures of Cervical Neoplasia&lt;/value&gt;&lt;recordNumber&gt;43&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;44&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;45&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Protocol for Comparing Promoter Hypermethylation Methods in NSCLC&lt;/value&gt;&lt;recordNumber&gt;46&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;47&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;48&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;National Ovarian Cancer Early Detection Program Blood and Genetics&lt;/value&gt;&lt;recordNumber&gt;49&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;50&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;51&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;New Biomarkers &amp; Dysplastic Respiratory Epithelium&lt;/value&gt;&lt;recordNumber&gt;52&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;53&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;54&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hereditary Cancer Institute family study specimen bank&lt;/value&gt;&lt;recordNumber&gt;55&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;56&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;57&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Informatics Pilot Project&lt;/value&gt;&lt;recordNumber&gt;58&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;59&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent diagnostic tool. At the center of these efforts is the application of SELDI-TOF-MS and artificial intelligence algorithms by the EDRN BDL site at Eastern
Virginia Medical School and the DMCC respectively. When the expression profiling process was applied to sera from individuals with prostate cancer (N=197), BPH (N=92) or from otherwise healthy donors (N=97) we achieved an overall misclassification rate of &amp;#060;10%. The sensitivity was 83% and the specificity was 100%
with an overall positive predictive value of 91.15%. This result is a significant improvement over PSA which presents as only 25% specificity and &amp;#062;90% sensitivity. Since this represents a noticeable improvement in current clinical approach we are proposing to embark upon a validation process. The described studies are
designed to address validation issues and include three phases. Phase 1; Synchronization of SELDI Output within the EDRN-Prostate-SELDI Investigational Collaboration (EPSIC); addressing portability (A) Synchronize SELDI instrumentation and robotic sample processing across the EPSIC using pooled serum(QC); (B) Establish the portability and reproducibility of the SELDI protein profiling approach within the EPSIC using normal and prostate cancer patient’s serum from a single site; (C) Establish robustness of the
approach toward geographic, sample collection and processing differences within EPSIC using case and
control serum from five different sites. Phase 2; Population Validation Establish geographic variability and robustness in a large cross-sectional study among different sample population. Phase 3; Clinical Validation;
validate the serum protein expression profiling coupled with a learning algorithm as a means for early detection of prostate cancer using longitudinal PCPT samples. We have assembled a cohesive multi-institutional team for completing these studies in a timely and efficient manner. The team consists of five EDRN laboratories,
DMCC and CBI and the proposed budget reflects the total involvement.&lt;/value&gt;&lt;recordNumber&gt;60&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers: Prostate&lt;/value&gt;&lt;recordNumber&gt;61&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;62&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;63&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers: Breast&lt;/value&gt;&lt;recordNumber&gt;64&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;65&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;66&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Presence of simian virus 40 DNA sequences in human&lt;/value&gt;&lt;recordNumber&gt;67&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;68&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;69&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Expression based markers for breast cancer detection&lt;/value&gt;&lt;recordNumber&gt;70&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;71&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;72&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast tissue array&lt;/value&gt;&lt;recordNumber&gt;73&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;74&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;75&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Dev Lab At Moffitt Supplement&lt;/value&gt;&lt;recordNumber&gt;76&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;77&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;78&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detecting Breast Cancer Signatures in Body Fluids&lt;/value&gt;&lt;recordNumber&gt;79&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;80&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;81&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Research Depository of Normal and Neoplastic Human Tissues&lt;/value&gt;&lt;recordNumber&gt;82&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;83&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;84&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers&lt;/value&gt;&lt;recordNumber&gt;85&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;86&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;87&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Genetics of Urinary Bladder Carcinoma&lt;/value&gt;&lt;recordNumber&gt;88&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion Criteria
1.   Must be &amp;#8805;5 years post prostate cancer diagnosis, between 30 and 99 years of age OR
2.   Diagnosed with prostate cancer with a Gleason’s score &amp;#8805; 4+3=7, or 3+3 with survivorship of 5 years, or positive for metastatic disease, or recurrence or has an unexplained increase in their serum PSA after treatment and
3.   Diagnosed with prostate cancer in the past in whom follow-up regarding recurrence is available.
4.   Must be able to provide informed consent and 
5.   Must be willing to store blood sample in the SABOR Biorepository (HSC20000030H).
Exclusion Criteria
1.   Does not meet the above inclusion criteria
&lt;/value&gt;&lt;recordNumber&gt;89&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Purpose/Objectives

To collect biological samples from subjects with prostate cancer to improve the accuracy of screening tests, identify markers that will predict how aggressive prostate cancers can be, and provide accurate information about how rapidly prostate cancer can worsen.

Research Design/Plan

Men with the following criteria will be consented for this protocol. 
1.) &amp;#8805;5 years post prostate cancer diagnosis, between the ages of 30 and 99 years of age (OR).  (Targeted recruits.)
2.) Diagnosed with prostate cancer with a Gleason’s score &amp;#8805; 4+3=7, or 3+3 with survivorship of 5 years, or is positive for metastatic disease, or recurrence or has an unexplained increase in their serum PSA after treatment.  (Targeted recruits.)
3.)  Diagnosed with prostate cancer in the past in whom follow-up is available.
Diagnostic and prognostic data will be collected as well as approximately 2 tablespoons of blood samples will be drawn from a vein in the subjects arm for processing and storage in the GU Tissue Bank (“Tissue Bank and Data Base for Urologic Diseases” HSC20050234H).  The study involves a single visit with annual telephone follow-up interviews to update the treatment and prognostic data.

Methods

Potential subjects will be identified through recruitment at clinics, through advertisement, at prostate cancer lectures, support group meetings, and by referral.  Once a potential subject has been identified, they will be informed about the study and the inclusion criteria to see if they qualify.  If the subject qualifies and provides informed consent, the study staff will collect and record demographic and disease information and completion of the AUA questionnaire.  The subjects will be called annually to updates by the research staff.

Clinical Relevance
Cancer statistics from the early 1990s reflect both a decline in prostate cancer mortality and a “downstaging” of the disease at the time of diagnosis. Thus, the number of men who have metastases at the time of diagnosis of their initial diagnosis of prostate cancer has decreased in parallel with a decline in mortality.  These favorable statistical trends followed the introduction of prostate specific antigen (PSA) as a screening assay for prostate cancer in the late 1980s and imply that earlier diagnosis and treatment provide benefit to the population. However, large scale screening activity must be carefully scrutinized for less desirable outcomes such as “over diagnosis” of biologically indolent disease and failure to diagnose aggressive disease.  When screening techniques are introduced into large populations, the number of false positives and false negatives is quite high even when the specificity of a test approaches 95%.  Men who are “false positives” needlessly undergo biopsy and the associated anxiety.  The detection rate using PSA alone is approximately 25%.  The information gained from this study may potentially increase the sensitivity and specificity of prostate cancer screenings, eliminate many of the false negatives and help detect early relapse of disease.
&lt;/value&gt;&lt;recordNumber&gt;90&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of protein and genetic biomarkers of prostate cancer and risk factors for progression of disease&lt;/value&gt;&lt;recordNumber&gt;91&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;92&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;93&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;MMR protein expression in HNPCC&lt;/value&gt;&lt;recordNumber&gt;94&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;95&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;96&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Methylation tumor markers in HNPCC&lt;/value&gt;&lt;recordNumber&gt;97&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;98&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;99&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Mutational load distribution analysis (MLDA) in pancreatic cancer&lt;/value&gt;&lt;recordNumber&gt;100&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;101&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;BACKGROUND: No proven ovarian cancer (OC) screening strategy exists for women who are at increased risk for the disease.  A risk of ovarian cancer algorithm (ROCA) using serial CA125 values have previously shown greater positive predictive value (PPV) and sensitivity than a single CA125 in screening women at general population risk.  We hypothesized that using ROCA would yield a reasonable PPV for ovarian cancer screening in a cohort at increased risk. METHODS: Between 7/2001 and 9/2006, 25 sites (14 CGN, 3 ovarian SPOREs, 1 EDRN, 7 others) prospectively enrolled patients. Inclusion criteria included: among self, 1st degree and 2nd degree relatives in same lineage either (i) BRCA 1/2 mutation, or (ii) two of OC or early onset (age &amp;#060; or = 50) breast cancer (BC), or (iii) Ashkenazi ethnicity and 1 of OC or BC.  A previous diagnosis of OC excluded subjects. Subjects underwent CA125 every 3 months and the risk of having ovarian cancer based on the CA125 profile was recalculated after each test. ROCA referred subjects with risk &amp;#062; 1% to ultrasound (US) and risk &amp;#062; 10% additionally to a gynecologic oncologist. Objectives included PPV for study indicated surgery, sensitivity, and compliance. Sample size was chosen to observe 8 OC endpoints with a power of 80% to rule out PPV &amp;#060; or = 10% if the true PPV = 20%.&lt;/value&gt;&lt;recordNumber&gt;102&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ovarian Cancer Screening Pilot Trial In High Risk Women&lt;/value&gt;&lt;recordNumber&gt;103&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;104&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;105&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum&lt;/value&gt;&lt;recordNumber&gt;106&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;107&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;108&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Molecular Detection of Invasive Bladder Cancer by Urine Examination&lt;/value&gt;&lt;recordNumber&gt;109&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;110&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;111&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Establishment of a serum standard for use in high-throughput proteomic&lt;/value&gt;&lt;recordNumber&gt;112&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;113&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;114&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detecting breast cancer protein signatures in body fluid&lt;/value&gt;&lt;recordNumber&gt;115&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;116&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;117&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Protein profiling for detection of high risk breast cancer&lt;/value&gt;&lt;recordNumber&gt;118&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;119&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;120&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas&lt;/value&gt;&lt;recordNumber&gt;121&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;122&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;123&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers&lt;/value&gt;&lt;recordNumber&gt;124&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;125&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;126&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies&lt;/value&gt;&lt;recordNumber&gt;127&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;128&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;129&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers&lt;/value&gt;&lt;recordNumber&gt;130&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;131&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;132&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Development Laboratory&lt;/value&gt;&lt;recordNumber&gt;133&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;134&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;135&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of New Markers in Normal and Abnormal Pap Smears&lt;/value&gt;&lt;recordNumber&gt;136&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;137&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;138&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early detection of liver cancer and hepatitis&lt;/value&gt;&lt;recordNumber&gt;139&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;140&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;141&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of FISH-based assay for early detection of high grade cervical dysplasia&lt;/value&gt;&lt;recordNumber&gt;142&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;143&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;144&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of cancer DNA markers in urine&lt;/value&gt;&lt;recordNumber&gt;145&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;146&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;147&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;148&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;149&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;150&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Ductal  Lavage Fluid Specimen Bank&lt;/value&gt;&lt;recordNumber&gt;151&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;152&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;153&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;154&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;155&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;156&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Assessment of Clinical Potential of Digital SNP Analysis&lt;/value&gt;&lt;recordNumber&gt;157&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;158&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;159&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ecogenetic Study of Lung Cancer&lt;/value&gt;&lt;recordNumber&gt;160&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;161&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;162&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pre-operative plevic mass study&lt;/value&gt;&lt;recordNumber&gt;163&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;ELIGIBILITY CRITERIA 

3.1.    Inclusion Criteria.
3.1.1.   Adults (&amp;#062; 18 years old)
3.1.2.   Patients with active or suspected Barrett’s esophagus including:
a.   Intestinal metaplasia without dysplasia, long and short segments
b.   Intestinal metaplasia with low-grade dysplasia
c.   Intestinal metaplasia with high-grade dysplasia
d.   Adenocarcinoma of the esophagus, primary diagnosis.
3.1.3.   Patients without Barrett’s after esophagoscopy.
3.1.4.   Able to physically tolerate removal of 30 – 60 ml of blood
3.1.5.   Tolerate extra research related biopsies
3.1.6.   Willing to permit extra blood/biopsies at endoscopic procedure 
3.1.7.   Ability and willingness to complete questionnaires
3.1.8.   Willing to sign informed consent.

3.2    Exclusion Criteria.
3.2.1.   Patients with active gastrointestinal bleeding.
3.2.2.   Patients with serious infections requiring IV antibiotics.
3.2.3.   Patients with coagulopathies or on anticoagulant treatment.
3.2.4.   Patients with known HIV or chronic viral hepatitis.
3.2.5.   Patients on active chemotherapy or radiation treatment.
3.2.6.   Patients who have had an esophagectomy.
3.2.7.   Patients with an active malignancy diagnosed or treated within 5 years except for squamous cell carcinoma of the skin, basal cell carcinoma of the skin; Carcinoma in situ, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery and/or radiation therapy; Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery.
&lt;/value&gt;&lt;recordNumber&gt;164&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;165&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett’s Esophagus Progression to Dysplasia and Adenocarcinoma&lt;/value&gt;&lt;recordNumber&gt;166&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See MSA protocol&lt;/value&gt;&lt;recordNumber&gt;167&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;168&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of Bladder CA by Microsatellite Analysis (MSA)&lt;/value&gt;&lt;recordNumber&gt;169&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;170&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;171&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI Phase I:  Assay Validation-Prostate&lt;/value&gt;&lt;recordNumber&gt;172&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;173&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;174&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI Validation Study Phase II&lt;/value&gt;&lt;recordNumber&gt;175&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion Criteria: Cases will include patients with HCC. Tumor staging will be performed using the modified TNM for HCC used by UNOS. Early stage HCC is determined by the most recent CT or MRI that has lesion(s) and maximum diameter.  UNOS stage I (a single lesion &amp;#060; 2 cm) or stage II (single lesion between 2-&amp;#060;5 cm or 2-3 lesions each &amp;#060; 3 cm), with no vascular invasion (portal vein thrombosis) or extrahepatic metastasis. 
Eligibility criteria for cases are:
&amp;#149;Age &amp;#062; 18 years of age
&amp;#149;Diagnosis HCC based on one of the following:
Histology (required if only one lesion &amp;#060; 2 cm is present) – Must have CT/MRI to calculate stage
Two imaging tests, with at least one (CT/MRI/Angiography) within the past 3 months or up to 2 weeks after consent showing evidence of arterial hypervascularization, and the other within the past 6 months (US, CT, MRI/Angiography) indicating a mass in the liver.
&amp;#149;MELD &amp;#060; 15.  If MELD &amp;#062;15, but INR is &amp;#060; 1.5, Total Bilirubin is &amp;#060; 1.7 and patient has a history of intrinsic renal disease, then eligible.
&amp;#149;Lab results (other than AFP) must be within the past 90 days.  AFP results are optional.
&amp;#149;Able and willing to provide written informed consent
The diagnostic criteria requiring two imaging tests in absence of a biopsy are based on an HCC Consensus Conference (8). While it is preferable to use histologic confirmation of HCC to determine eligibility, it is recognized that biopsies are not commonly done in patients with suspected HCC because of concerns of complications; histology will only be required for patients with only one lesion present that is less than 2 cm.

Controls
Eligibility criteria for controls are:
&amp;#149;Age &amp;#062; 18 years of age
&amp;#149;Diagnosis of cirrhosis based on liver histology. In the absence of histology, cirrhosis would be defined by an ultrasound or CT scan showing a cirrhotic-appearing liver with splenomegaly and platelet count of &amp;#060; 120 mm-3. If there is no splenomegaly (or absent) or a platelet coun&lt;/value&gt;&lt;recordNumber&gt;176&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;177&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Serum Markers for the Early Detection of Hepatocellular Carcinoma&lt;/value&gt;&lt;recordNumber&gt;178&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;179&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;180&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of Serum Proteomic Patterns and SNPs in Breast Cancer: A Pilot Study&lt;/value&gt;&lt;recordNumber&gt;181&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;182&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;183&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of paraffin-based expression profiles to predict minimal vs. substantial risk of disease progression using retrospective datasets&lt;/value&gt;&lt;recordNumber&gt;184&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;185&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.&lt;/value&gt;&lt;recordNumber&gt;186&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers for Prostate and Bladder Cancer&lt;/value&gt;&lt;recordNumber&gt;187&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;REFERENCE SETS A and C:

5.1 Clinical setting: Diagnosis of lung cancer

5.2 Cases eligibility Set A:

- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

   - No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last    5 years

   - Blood collected prior to treatment (chemo/radiation)

5.3 Controls eligibility Set A
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an “other cancer” control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate)

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status,    and PKY history of smoking

5.4 Sample sizes Set A
(1) Rapid single biomarker pre-validation:    87 cases and 50 controls, 25 other cancer controls
   (2) Panel of biomarkers pre-validation:   150 cases and 150 controls
(3) Phase II validation:         180 cases and 180 controls, 75 other cancer controls

5.5 Institution provider candidates Set A   
Pittsburgh
Vanderbilt
MDACC
UCLA
   UCHSC
   NYU
   JHU
 
REFERENCE SET B:

5.6 Clinical setting Set B
CT screening trial for the early detection of lung cancer

5.7 Cases eligib&lt;/value&gt;&lt;recordNumber&gt;188&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin validating a series of candidate biomarkers for the early detection of lung cancer. The initial goal of the LCBG is to develop the requisite sample resources to validate serum/plasma biomarkers for the early diagnosis of lung cancer.  Researchers may use these resources and process for continued biomarker refinement but this is not the primary activity of the LCBG.&lt;/value&gt;&lt;recordNumber&gt;189&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Lung&lt;/value&gt;&lt;recordNumber&gt;190&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;n/a&lt;/value&gt;&lt;recordNumber&gt;191&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Create a distributed on-line virtual specimen repository.&lt;/value&gt;&lt;recordNumber&gt;192&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Resource Network Exchange&lt;/value&gt;&lt;recordNumber&gt;193&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;194&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;195&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Polyp Prediction Study&lt;/value&gt;&lt;recordNumber&gt;196&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See BRSCW description document&lt;/value&gt;&lt;recordNumber&gt;197&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;198&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Reference Sets for Cancers in Women&lt;/value&gt;&lt;recordNumber&gt;199&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;200&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;201&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study&lt;/value&gt;&lt;recordNumber&gt;202&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1.3 Patient eligibility:
1.Male over age 40.
2.Patient scheduled for prostate biopsy for any of the following reasons:
   - PSA &amp;#062; 2.5 ng/ml
   - Rising PSA (&amp;#062;0.5 ng/ml/yr)
   - Lower PSA value with other risk factors for prostate cancer (e.g.; family history)
   - abnormal DRE
   - percent free PSA &amp;#060;15%
3.No prior history of prostate cancer or prostate biopsy.
4.Prostate biopsy with at least 10 cores taken in a laterally directed fashion.
5.Blood collected prior to prostate biopsy.  
6.Prostate biopsy pathology report available.

&lt;/value&gt;&lt;recordNumber&gt;203&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;204&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Prostate&lt;/value&gt;&lt;recordNumber&gt;205&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3 Subject Selection
3.1 Eligibility Criteria
3.1.1 Cases (n=300 invasive cancer and 100 DCIS: Up to 100 LCIS and 100 Pagets may
be included but are not the targeted population) and Benign Disease Controls (n=100 benign
non-proliferative conditions and 100 benign proliferative conditions)
a. Female
b. At least 18 years of age
c. Mammographic finding or palpable breast mass
d. Undergoing initial diagnosis to determine if breast cancer is present
3.1.2 Normal Controls (n=100):
a. Female
b. At least 18 years of age
c. Undergoing routine mammographic screening (with or without clinical breast
exam)
d. BIRADS score less than or equal to 2
3.2 Exclusion Criteria
3.2.1 Cases and Benign Disease Controls
a. Already diagnosed by biopsy for current presentation of breast cancer or benign
disease
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Recurrence of previous breast cancer
d. Pregnant or nursing
The consenting process and blood draw will be carried out before primary pathology results
are obtained. This may occur either before or after the diagnostic biopsy, but will be limited
to the same day that the biopsy is performed or up to 2 weeks prior to biopsy. There are two
reasons for this restriction: 1) It will ensure that the cancer (or benign) mass is present at the
time of blood sampling and 2) It will reduce potential biases that might result from subjects
knowing their diagnosis with certainty to be malignant or benign. No exclusion will be
made based upon age, race, extent of disease, drug usage, family history, prior biopsies, prior
benign diseases or prior DCIS.
3.2.2 Normal Controls
a. Current evidence of breast abnormality (prior benign disease or DCIS
acceptable)
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Pregnant or nursing
d. BIRADS score greater than 2 or palpable mass
For the purpose of this study, we defin&lt;/value&gt;&lt;recordNumber&gt;206&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;207&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Breast Cancer and Imaging&lt;/value&gt;&lt;recordNumber&gt;208&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;209&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;210&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Longitudinal Serum Biorepository&lt;/value&gt;&lt;recordNumber&gt;211&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;212&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;213&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Novel Surveillance Strategies For Hereditary Nonpolyposis Colon Cancer Family Members&lt;/value&gt;&lt;recordNumber&gt;214&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;215&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;216&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Basis of Barrett&amp;#39;s -Associated Carcinogenesis&lt;/value&gt;&lt;recordNumber&gt;217&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;218&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;219&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN-WHI Pre-Clinical Colon Ca Specimens&lt;/value&gt;&lt;recordNumber&gt;220&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;221&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Determine which markers move to validation using the prospectie prostate reference set samples.&lt;/value&gt;&lt;recordNumber&gt;222&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Pre-Validation Set&lt;/value&gt;&lt;recordNumber&gt;223&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;224&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;225&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Spectral Markers for Early Detection of Colon Neoplasia&lt;/value&gt;&lt;recordNumber&gt;226&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3.2 Inclusion Criteria
3.2.1 Cases
Cases will include patients with HCC. Tumor staging will be performed using the modified TNM for HCC
used by UNOS. Early stage HCC is determined by the most recent CT or MRI that has lesion(s) and
maximum diameter. UNOS stage I (a single lesion &amp;#060; 2 cm) or stage II (single lesion between 2-&amp;#060;5 cm or
2-3 lesions each &amp;#060; 3 cm), with no vascular invasion (portal vein thrombosis) or extrahepatic metastasis.
Eligibility criteria for cases are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis HCC based on one of the following:
&amp;#1048707; Histology (required if only one lesion &amp;#060; 2 cm is present) – Must have CT/MRI to calculate
stage
&amp;#1048707; Two imaging tests, with at least one (CT/MRI/Angiography) within the past 3 months or up to
2 weeks after consent showing evidence of arterial hypervascularization, and the other within
the past 6 months (US, CT, MRI/Angiography) indicating a mass in the liver.
&amp;#149; MELD &amp;#060; 15. If MELD &amp;#062;15, but INR is &amp;#060; 1.5, Total Bilirubin is &amp;#060; 1.7 and patient has a history of
intrinsic renal disease, then eligible.
&amp;#149; Lab results (other than AFP) must be within the past 90 days. AFP results are optional.
&amp;#149; Able and willing to provide written informed consent
The diagnostic criteria requiring two imaging tests in absence of a biopsy are based on an HCC Consensus
Conference (8). While it is preferable to use histologic confirmation of HCC to determine eligibility, it is
recognized that biopsies are not commonly done in patients with suspected HCC because of concerns of
complications; histology will only be required for patients with only one lesion present that is less than 2
cm.
3.2.2 Controls
Eligibility criteria for controls are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis of cirrhosis based on liver histology. In the absence of histology, cirrhosis would be
defined by an ultrasound or CT scan showing a cirrhotic-appearing liver with splenomegaly and
platelet count of &amp;#060; 120 mm-3.&lt;/value&gt;&lt;recordNumber&gt;227&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Utilize the remaining specimens collected under the DCP protocol to develop and validate markers for the early detection of HCC&lt;/value&gt;&lt;recordNumber&gt;228&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Liver&lt;/value&gt;&lt;recordNumber&gt;229&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;230&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;231&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Soluble  Mesothelin Related Peptide (SMRP) and Osteopontin (OPN) as Early Detection Markers for Malignant Mesothelioma (MM)&lt;/value&gt;&lt;recordNumber&gt;232&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;100 cases and 200 controls will be selected based on retrospective chart review of endoscopic
and pathology reports demonstrating BE, defined as salmon-colored mucosa in the tubular esophagus with intestinal metaplasia with goblet cells on biopsy. The endoscopic procedures were done as per routine clinical care at participating Consortia institutions. Cases are those BE patients who initially had either no or low grade
dysplasia, who eventually progressed to have either HGD or EAC (progressors). Controls will include patients with BE who have not progressed beyond low grade dysplasia (non-progressors).
&lt;/value&gt;&lt;recordNumber&gt;233&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;234&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Barrett&amp;#39;s Esophagus Methylation Profiles&lt;/value&gt;&lt;recordNumber&gt;235&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;236&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;237&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques&lt;/value&gt;&lt;recordNumber&gt;238&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;239&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;240&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers in Familial Multiple Myeloma&lt;/value&gt;&lt;recordNumber&gt;241&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3.1 Cases (Pancreatic Cancer)
Patients will be consented prior to surgery.
A. No prior history of any other malignancy except nonmelanoma skin cancers for ten years.
B. Must have undergone complete surgical resection of the tumor with curative intent including the
presence of negative margins and a pathologic staging of I or IIA.
C. Must have histological verification of a pancreatic adenocarcinoma
D. Must not have received preoperative chemoradiation (neoadjuvant) therapy due to our inability to
adequately stage these patients.
E. Able to give informed consent.
F. Blood sample must be obtained within the past 2 weeks prior to surgery/anesthesia according to
procedure described in Appendix D.
Post-Enrollment Criteria: Inclusion of the patient in the proposed validation set is dependent on the results
of the surgery. The patient must have undergone complete surgical resection of the tumor with curative
intent including the presence of negative margins and a pathologic staging of I or IIA. Samples from any
patients not meeting these criteria will be used in a discovery set.
3.2 Controls
Three different control groups are proposed for this reference set: chronic pancreatitis patients, acute
benign biliary obstruction patients and healthy controls. The cases and controls are required to have a
similar age distribution. Although we will attempt to keep the same number of cases and controls within
each site (1 to 3 ratio), age distribution does not have to be similar for cases and controls within each site.
An algorithm developed by Feng and colleagues will be used to recruit cases and controls across multicenters
to ensure that the cases and controls are frequency matched by age. Eligibility criteria for each of
Page 4 of 7
the controls groups are described below. Control specimens will not be collected until 10 post-operative
PC cases have been successfully enrolled in the study.&lt;/value&gt;&lt;recordNumber&gt;242&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The primary objective of the EDRN Pancreatic Cancer Working Group Proposal is to create a reference set consisting of well-characterized serum/plasma specimens to use as a resource for the development of biomarkers for the early detection of pancreatic adenocarcinoma. The testing of biomarkers on the same sample set permits direct comparison among them; thereby, allowing the development of a biomarker panel
that can be evaluated in a future validation study. Additionally, the establishment of an infrastructure with core data elements and standardized operating procedures for specimen collection, processing and storage, will provide the necessary preparatory platform for larger validation studies when the appropriate marker/panel for pancreatic adenocarcinoma has been identified.&lt;/value&gt;&lt;recordNumber&gt;243&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Pancreatic&lt;/value&gt;&lt;recordNumber&gt;244&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;245&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;246&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement&lt;/value&gt;&lt;recordNumber&gt;247&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;248&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers.  The resource will include comprehensive proteomic (tandem mass spectrometry, MS/MS) data generated from plasma samples that have been collected between four months and four years prior to clinical detection of ovarian cancer.  These pre-clinical samples, provided from the Beta Carotene and Retinol Efficacy Trial (CARET) prospective study, will be interrogated using IPAS, the proteomic profiling method developed by the Hanash Laboratory and with the quantitative methods developed by the McIntosh laboratory.  In addition, we will combine these pre-clinical data with already completed IPAS interrogations of plasma collected at the time of ovarian cancer diagnosis.  Thus together we will provide information on both pre-clinical and clinical behavior of a large number of proteins.  Based on our preliminary work we are able to quantify over 500 plasma proteins in each of these experiments, many of which are putative ovarian cancer biomarkers, showing the platform is capable of providing useful information regarding biomarker candidates.&lt;/value&gt;&lt;recordNumber&gt;249&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN&lt;/value&gt;&lt;recordNumber&gt;250&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;251&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;252&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds&lt;/value&gt;&lt;recordNumber&gt;253&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1.3 Patient eligibility:
1.Male over age 40.
2.Patient scheduled for prostate biopsy for any of the following reasons:
   - PSA &amp;#062; 2.5 ng/ml
   - Rising PSA (&amp;#062;0.5 ng/ml/yr)
   - Lower PSA value with other risk factors for prostate cancer (e.g.; family history)
   - abnormal DRE
   - percent free PSA &amp;#060;15%
3.No prior history of prostate cancer or prostate biopsy.
4.Prostate biopsy with at least 10 cores taken in a laterally directed fashion.
5.Blood collected prior to prostate biopsy.  
6.Prostate biopsy pathology report available.

&lt;/value&gt;&lt;recordNumber&gt;254&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;see Publication&lt;/value&gt;&lt;recordNumber&gt;255&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008)&lt;/value&gt;&lt;recordNumber&gt;256&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;257&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;258&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma&lt;/value&gt;&lt;recordNumber&gt;259&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion Criteria

Patients must fulfill all of the following criteria to be eligible:
1.  Histologically confirmed adenocarcinoma of
    the prostate.
2.  Clinically localized prostate cancer: T1-2,
    NX or N0, MX or M0.
3.  No previous treatment for prostate cancer
   (including hormonal therapy, radiation 
    therapy, surgery, or chemotherapy).
4.  ECOG Performance Status 0 or 1.
5.  Patient has elected Active Surveillance as
    preferred management plan for prostate cancer.
6.  Patient consent has been obtained according
    to local Institutional Review Board for
    acquisition of research specimens. 
7.  Patient is accessible and compliant for
    follow-up.
8.  Prostate biopsy requirements:

    a. If diagnosis was within one year of
       baseline visit, participant must have at 
       least one biopsy with at least 10 cores.
    b. If diagnosis was more than 1 year prior to
       baseline visit, participant must have a
       minimum of 2 biopsies, one of which must
       be within 2 years prior to baseline visit.

Exclusion Criteria
Patients who fulfill any of the following criteria are not eligible:

1. Unwillingness or inability to undergo serial
   prostate biopsy.

2. History of other malignancies, except: 
   adequately treated non-melanoma skin cancer or
   adequately treated superficial bladder cancer
  (Ta) or other solid tumors curatively treated
   with no evidence of disease for &amp;#062; 5 years.&lt;/value&gt;&lt;recordNumber&gt;260&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;261&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Active Surveillance Study&lt;/value&gt;&lt;recordNumber&gt;262&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion – Male and female patients must be diagnosed with acute or chronic pancreatitis, biliary obstruction, pancreatic cancer, or other gastrointestinal malignancies. Attempts will be made to recruit minorities. 
Exclusion – Do not expect to enroll children since pancreatic adenocarcinoma is a disease of adults that typically occurs in the 5th, 6th and 7th decades of life.
&lt;/value&gt;&lt;recordNumber&gt;263&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;264&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies&lt;/value&gt;&lt;recordNumber&gt;265&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Adult males (ages 18-999) with a diagnosis of prostate cancer &lt;/value&gt;&lt;recordNumber&gt;266&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;267&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Pre-Validation of Multiplex Biomarker in Urine&lt;/value&gt;&lt;recordNumber&gt;268&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;269&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential cancer biomarkers, especially those encoding secreted or extracellular proteins. These proteins might be detected in urine. CD90/THY1 is one such candidate. A clinical test based on urinary CD90 would be useful in reducing the number of unnecessary biopsies done because of abnormal serum PSA and/or DRE finding. Elevated CD90 protein is found in tumor tissue and urine.&lt;/value&gt;&lt;recordNumber&gt;270&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection&lt;/value&gt;&lt;recordNumber&gt;271&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Eligible subjects will be patients who have been referred for cystoscopy to evaluate microhematuria, voiding dysfunction or others concerns.
A) Inclusion criteria include:
1. Patient who is schedule to undergo cystoscopy as indicated in the evaluation of a specific urological condition (eg hematuria or voiding dysfunction)
2. Patient who is willing and able to provide a voided urine specimen for the study.
3. Patient who has signed informed consent
a. allowing processing/evaluation of urine for biomarker evaluation including DNA studies
b. allowing access of the research staff to the patient&amp;#39;s medical record e.g. to determine if bladder cancer diagnosed at cystoscopy or thereafter
B. Exclusion criteria include:
1. Patient not willing to sign informed consent
2. Patient unable to provide a voided urine sample
3. Previously treated malignancy
4. Previous recontructive genitourinary surgery (for example prior prostatectomy in men or augmentation cystoplasty in women would confound urinary methylation marker analysis)
5. Previous pelvic irradiation
6. Previous intravesical pharmacotherapy (eg BCG or DMSO)
7. Presence of urinary infection
8. Indwelling urinary catheter or stent

A. Cases are subjects whose cystoscopry or related clinical testing (eg biopsy pathology or urine cytology) indicates presence of transitional cell carcinoma.
B. Controls are subjects who are not found to have urothelial cancer after cystoscopy, biopsy pathology or urine cystology.
C. Participating subjects found to have non-transitional cell carcinoma (eg squamous cell carcinoma or adenocarcinoma) will be evaluated separately for the cases and controls, eg methylation will be studied for descriptive purposes but excluded from case-controls comparison.
&lt;/value&gt;&lt;recordNumber&gt;272&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Study never Launched&lt;/value&gt;&lt;recordNumber&gt;273&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Methylation &amp; Proteomics-Based Detection of Bladder Cancer&lt;/value&gt;&lt;recordNumber&gt;274&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;275&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;276&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles&lt;/value&gt;&lt;recordNumber&gt;277&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;278&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;279&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pre-Validation of Metabolomic Biomarkers of Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;280&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;281&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;282&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory&lt;/value&gt;&lt;recordNumber&gt;283&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;284&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;285&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer - Supplemental Pre-Validation Protocol&lt;/value&gt;&lt;recordNumber&gt;286&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;287&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;288&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PTM Microarray: Request for Year 3 Set-Aside Funds&lt;/value&gt;&lt;recordNumber&gt;289&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;290&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;291&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Cancer Early Detection Stem Cell Biomarkers (CA117452 Set-Aside)&lt;/value&gt;&lt;recordNumber&gt;292&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;293&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;294&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer&lt;/value&gt;&lt;recordNumber&gt;295&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;296&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;297&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;High-Throughput Evaluation of Breast Cancer Markers&lt;/value&gt;&lt;recordNumber&gt;298&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;299&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;300&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Year 2 Collaborative Project - UCSF and Battelle PNWD&lt;/value&gt;&lt;recordNumber&gt;301&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;302&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;303&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge&lt;/value&gt;&lt;recordNumber&gt;304&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;305&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;306&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Progression of Methylation in Bladder Cancer&lt;/value&gt;&lt;recordNumber&gt;307&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;308&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;309&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Integrated Development of Novel Molecular Markers&lt;/value&gt;&lt;recordNumber&gt;310&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;311&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;312&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection of Breast Cancer Using Autoantibody Markers&lt;/value&gt;&lt;recordNumber&gt;313&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;314&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;315&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Approach for Diagnostic Applications in Head and Neck Cancer&lt;/value&gt;&lt;recordNumber&gt;316&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Ovarian Cancer (350)(Sensitivity Trial) : The disease group includes women having newly diagnosed ovarian cancer (pelvic mass). The study will be done using archived specimens if they meet the specimen collection protocol  The diagnosis of ovarian cancer is done according to clinical, surgical, histological and pathologic diagnosis. The major histology groups (serous [borderline and invasive], mucinous, endometrioid, clear cell, and undifferentiated) will be represented proportional to their incidences.  Preliminary communication with PLCO investigators indicates that the histological distribution seen in PLCO matches ours expected design.  Within each histology, we will oversample early-stage disease where possible, with a goal of one-half early stage and one-half late stage. Control Group (1000)(Specificity Trial) a) Normal: The healthy control group includes age-matched healthy individuals, that come into the clinic for a regular gynecologic examination, who do not have a diagnosis of any type of cancer, or who are not genetically predisposed to develop ovarian cancer.  This group is available from the PLCO and will represent the majority (80%) of the samples evaluated. Similar criteria will be used for samples collected from all the sites.  b) High-Ris (50 samples): degree of risk is determined by formal genetic evaluation and categorized as mild (only one affected first-degree relative or a personal history of breast cancer), moderate (&amp;#8805; 2 affected first degree relatives), or high (BRCA1 or BRCA2 mutation inherited from an affected relative). It is estimated that over 50% of women with BRCA1 mutations that develop ovarian cancer are less than age 50.  Women with a BRCA1 mutation have approximately a 30-40% risk of developing ovarian cancer by age 70. Also included in this group are women with non-gynecologic malignancies, gynecological malignancies other than ovarian, and benign gynecologic conditions(50samples). In addition we will include 50 samples fro&lt;/value&gt;&lt;recordNumber&gt;317&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;318&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Phase II Validation of a New Panel of Biomarkers for Early Detection of Ovarian Cancer&lt;/value&gt;&lt;recordNumber&gt;319&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;320&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;321&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Light Scattering Spectroscopy for the Detection of Colorectal Neoplasia&lt;/value&gt;&lt;recordNumber&gt;322&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;323&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;324&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;325&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Colon Ref Set&lt;/value&gt;&lt;recordNumber&gt;326&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;327&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Reference Set Application: Moncef Jendoubi - Milagen (2006)&lt;/value&gt;&lt;recordNumber&gt;328&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Colon Ref Set&lt;/value&gt;&lt;recordNumber&gt;329&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;330&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Reference Set Application: Nam Kim - DiaDexus (2008)&lt;/value&gt;&lt;recordNumber&gt;331&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see description of colon cancer reference set&lt;/value&gt;&lt;recordNumber&gt;332&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;333&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Reference Set Application: Mary Disis - University of Washington (2008)&lt;/value&gt;&lt;recordNumber&gt;334&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See summary of Colon Reference Set&lt;/value&gt;&lt;recordNumber&gt;335&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;336&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon  Reference Set Application: Robert Getzenberg - Johns Hopkins (2008)&lt;/value&gt;&lt;recordNumber&gt;337&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see GLNE001-Preliminary Clinical Characterization of Serum, Plasma and Urine Biomarkers for Colorectal Neoplasms and GLNE007-Evaluation of Stool Based Markers for the Early Dectection of Colorectal Cancers and Adenomas&lt;/value&gt;&lt;recordNumber&gt;338&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The Early Detection Research Network, Great Lakes-New England Clinical,
Epidemiological and Validation Center (GLNE CVC) announces the availability of
serum, plasma and urine samples for the early detection for colon cancer and validation
studies.&lt;/value&gt;&lt;recordNumber&gt;339&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set: Colon&lt;/value&gt;&lt;recordNumber&gt;340&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;341&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;342&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer&lt;/value&gt;&lt;recordNumber&gt;343&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;344&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;345&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development and Clinical Validation of Biomarkers for Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;346&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;347&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;348&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies&lt;/value&gt;&lt;recordNumber&gt;349&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;350&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;351&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prognostic Markers in Lynch Syndrome Colorectal Cancers&lt;/value&gt;&lt;recordNumber&gt;352&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;353&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Participate in a prevalidation study for methylation based detection of bladder cancer.  In addition, a panel of three markers identified will be evaluated for their ability to a) identify bladder cancer patients from those with benign urologic disease; b) identify patients with superficial (papillary) cancers from those with high grade invasive cancers&lt;/value&gt;&lt;recordNumber&gt;354&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;A Methylation Panel for Bladder Cancer&lt;/value&gt;&lt;recordNumber&gt;355&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;356&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;357&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;The Early Detection Research Network: Biomarker Reference Laboratories&lt;/value&gt;&lt;recordNumber&gt;358&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;359&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;360&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Gianluigi Giannelli - Univ of Bari (2008)&lt;/value&gt;&lt;recordNumber&gt;361&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion
&amp;#149;   Males greater than or equal to age 18
&amp;#149;   Patient scheduled for prostate biopsy for any of the following reasons:
o   PSA &amp;#062;2.0 ng/ml
o   Elevated PSA velocity (&amp;#062;0.4 ng/ml/yr)
o   Lower PSA value with other risk factors for PCa (e.g.; family history)
o   Prior ASAP or HGPIN
o   Abnormal DRE
o   % free PSA &amp;#060;15%
&amp;#149;   Finasteride/dutasteride and other medications for BPH and ED are allowable but will be recorded 
Exclusion
&amp;#149;   History of PCa
&amp;#149;   Urine not collected post DRE prior to index prostate biopsy
o   Blood can be collected up to 1 month before urine
o   Urine can be collected up to 1 month before index biopsy
&amp;#149;   Index prostate biopsy with &amp;#060;10 cores and without extended template
&amp;#149;   Index prostate biopsy pathology report unavailable
&amp;#149;   Participating in an intervention trial for prostate disease
&amp;#149;   Prior surgical (open or endoscopic) or minimally invasive treatment (TUNA/TUMT) for BPH
&amp;#149;   Prior saturation biopsy defined as at least 30 cores
&amp;#149;   Prior prostate biopsy within 6 months
&amp;#149;   Prior PCA3 test performed for clinical purpose
&amp;#149;   Consented more than 3 months before index biopsy
&lt;/value&gt;&lt;recordNumber&gt;362&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;363&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PCA3 Validation Study and Urinary Reference Set&lt;/value&gt;&lt;recordNumber&gt;364&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See Lung Reference Set A&lt;/value&gt;&lt;recordNumber&gt;365&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;366&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set A Application:  Edward Hirschowitz - University of Kentucky (2009)&lt;/value&gt;&lt;recordNumber&gt;367&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See Lung Reference Set A&lt;/value&gt;&lt;recordNumber&gt;368&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;369&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set A Application: Lee Goodglick/ Eleftherios Diamandis- UCLA/MSH  (2009)&lt;/value&gt;&lt;recordNumber&gt;370&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;This study will retrospectively sample tissue from patients who have undergone radical prostatectomy at the participating institutions. Sites will construct a set of “validation” TMAs containing tissue from a total of 105 cases of recurrent prostate cancer and 105 cases of non-recurrent prostate cancer. If resources allow, sites will construct a second set of “discovery” TMAs containing tissue from an additional 105 cases of recurrent prostate cancer and 105 cases of non-recurrent prostate cancer. 

Recurrent prostate cancer  (Failure)
&amp;#149;   Disease with evidence of recurrence at any time after radical prostatectomy as measured by:
1) a single serum prostate-specific antigen (PSA) level greater than 0.2 ng/mL after RP 
and/or 2) receipt of salvage therapy after RP 
and/or 3) clinical or radiological evidence of metastatic disease.

Non-recurrent prostate cancer (non-Failure)
&amp;#149;   Disease with no evidence of recurrence for the entire follow-up period (minimum 5 years follow-up) after radical prostatectomy as measured by :
1) serum PSA level less than 0.2 ng/mL for the entire follow-up period 
     and 2) no receipt of salvage therapy 
     and 3) no clinical or radiological evidence of metastatic disease.

Exclusion criteria 
&amp;#149;   Patients with PSA levels less than 0.2 ng/mL for 6 months after RP who received adjuvant therapy will be excluded from this study. 
&amp;#149;   Patients who received neoadjuvant hormone therapy will be excluded from the study, providing that the neoadjuvant hormone therapy status is known. If the status is unknown, patients will be included but records will indicate status unknown. &lt;/value&gt;&lt;recordNumber&gt;371&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict recurrent prostate cancer at the time of radical prostatectomy (RP). Candidate biomarkers will be assessed by performing tissue localization studies on TMAs containing recurrent prostate cancer and non-recurrent prostate cancer. De-identified data will be transferred to a central repository for statistical analysis. 

Participating institutions will use a variation of case-cohort sampling to randomly select a subset of patients from a retrospectively constructed RP cohort and/or perform selected assays on the cohort. The study endpoint is time to recurrence; of primary interest is five year recurrence free survival. Recurrent prostate cancer is defined by 1) a single serum prostate-specific antigen (PSA) level greater than 0.2 ng/mL after RP and/or 2) receipt of salvage or secondary therapy after RP and/or 3) clinical or radiological evidence of metastatic disease. Non-recurrent prostate cancer is defined as disease with no evidence of recurrence. 
&lt;/value&gt;&lt;recordNumber&gt;372&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Canary TMA&lt;/value&gt;&lt;recordNumber&gt;373&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Ever smokers: person who has smoked &amp;#062;100 cigarettes during lifetime; Never Smokers: person who has smoked less than 100 cigarettes during lifetime; Current Smokers: person currently smoking who has quit for &amp;#062; one year; former smokers: smoker who has quit smoking for &amp;#062; one year; long-term former smokers: smoker who has quit smoking for &amp;#062; 10 years;
light smokers: smoker with total exposure of &amp;#062; 10 years.&lt;/value&gt;&lt;recordNumber&gt;374&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The overall goal of this project is to identify, verify and apply biomarkers for the early diagnosis or risk assessment of lung cancer in never smokers. The first year will be regarded as a year of discovery. After successful demonstration of the feasibility of the approach for novel marker discovery, funding will be applied for to perform confirmation and preclinical studies on
the biomarkers and validation studies (specific aims 2 and 3, to be performed in years two and three). Year two can be regarded as the year of confirmation and year three as the year of validation.&lt;/value&gt;&lt;recordNumber&gt;375&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of biomarkers for lung cancer in never smokers&lt;/value&gt;&lt;recordNumber&gt;376&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see description of Cancer in Women Reference Set&lt;/value&gt;&lt;recordNumber&gt;377&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;378&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Eleftherios Diamandis - Mt Sinai (2006)&lt;/value&gt;&lt;recordNumber&gt;379&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;At least a 10 core biopsy with blood collected prior and serum stored at -70C for up to six years prior to analysis.&lt;/value&gt;&lt;recordNumber&gt;380&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;381&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Application: Daniel Chan/Patty Beckman- JHU/University of Minnesota (2007)&lt;/value&gt;&lt;recordNumber&gt;382&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Sample Eligibility defined in DCP Protocol&lt;/value&gt;&lt;recordNumber&gt;383&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;384&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Timothy Block - Drexel Univ (2008)&lt;/value&gt;&lt;recordNumber&gt;385&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Refer to reference set description&lt;/value&gt;&lt;recordNumber&gt;386&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;387&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Application:  Brian Haab - Van Andel (2006)&lt;/value&gt;&lt;recordNumber&gt;388&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Rapid Prostate Reference Set&lt;/value&gt;&lt;recordNumber&gt;389&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;390&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Application: Eleftherios Diamandis - Mt Sinai (2006)&lt;/value&gt;&lt;recordNumber&gt;391&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW protocol&lt;/value&gt;&lt;recordNumber&gt;392&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;393&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Anna Lokshin - Univ of Pitts (2008)&lt;/value&gt;&lt;recordNumber&gt;394&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW&lt;/value&gt;&lt;recordNumber&gt;395&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;396&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Anu Mathew - Meso Scale (2006)&lt;/value&gt;&lt;recordNumber&gt;397&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;398&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;399&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;MALDI Dilution Data: Randolph&lt;/value&gt;&lt;recordNumber&gt;400&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW&lt;/value&gt;&lt;recordNumber&gt;401&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;402&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Michael Wilson - EIC Laboratories, Inc (2007)&lt;/value&gt;&lt;recordNumber&gt;403&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Rapid Prostate Reference Set&lt;/value&gt;&lt;recordNumber&gt;404&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;405&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Application: Robert Getzenberg - John Hopkins (2006)&lt;/value&gt;&lt;recordNumber&gt;406&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW description&lt;/value&gt;&lt;recordNumber&gt;407&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;408&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Joe Buechler - Biosite Inc (2009)&lt;/value&gt;&lt;recordNumber&gt;409&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;&lt;recordNumber&gt;410&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;411&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application (#1): David Lubman - Univ of Michigan (2009)&lt;/value&gt;&lt;recordNumber&gt;412&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;borderline ovarian cancers were excluded
postmenopausal women only&lt;/value&gt;&lt;recordNumber&gt;413&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;414&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PLCO Ovarian Phase III Validation Study&lt;/value&gt;&lt;recordNumber&gt;415&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion criteria:
- benign breast pathologies, 
- all types of breast malignancy, 
- pre/peri/post-menopausal status, 
- familial/genetic predisposition

exclusion criteria:
-   Pregnancy, 
-   Breast-feeding, 
-   alcohol and drug abuse.

&lt;/value&gt;&lt;recordNumber&gt;416&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Breast-conserving lumpectomy followed by radiation therapy has been shown to be an alternative strategy, competitive to mastectomy, in preventing mortality caused by breast cancer. However, besides negative short-term effects (blood flow disturbances, painful erythema, etc.) breast irradiation causes severe long-term side-effects (leucopenia, anemia, breast edema, fibrosis, increase of angiosarcoma, leukemia, myelodysplastic syndromes). Therefore, the identification of individual susceptibility to radiation and improved patient-specific radiotherapy planning are highly desirable for personalised treatment in breast cancer. 
Why early and predictive diagnosis is crucial for long-term outcomes of breast cancer?
 Breast cancer is the most common cause of cancer death among women with an average incidence rate of 10-12 per 100 women. In 2005, breast cancer led to 502,000 deaths worldwide. Advanced stages of breast cancer lead to the development of metastasis predominantly in the lymph nodes, bone, lung, skin, brain, and liver. Although breast-MRI is currently the most sensitive diagnostic tool for breast imaging, its specificity is limited resulting in a negative impact for surgical management in approximately 9 % of cases. Early diagnosis has been demonstrated to be highly beneficial, enabling significantly enhanced therapy efficiency and possibly full recovery.
&lt;/value&gt;&lt;recordNumber&gt;417&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized treatment&lt;/value&gt;&lt;recordNumber&gt;418&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Prostate Reference Set description: 
1.3 Patient eligibility:
1.Male over age 40.
2.Patient scheduled for prostate biopsy for any of the following reasons:
   - PSA &amp;#062; 2.5 ng/ml
   - Rising PSA (&amp;#062;0.5 ng/ml/yr)
   - Lower PSA value with other risk factors for prostate cancer (e.g.; family history)
   - abnormal DRE
   - percent free PSA &amp;#060;15%
3.No prior history of prostate cancer or prostate biopsy.
4.Prostate biopsy with at least 10 cores taken in a laterally directed fashion.
5.Blood collected prior to prostate biopsy.  
6.Prostate biopsy pathology report available.

&lt;/value&gt;&lt;recordNumber&gt;419&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;420&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Reference Set Application: William Isaacs-John Hopkins (2010)&lt;/value&gt;&lt;recordNumber&gt;421&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Eligibility criteria for controls are:
&amp;#149;Able and willing to provide written informed consent
&amp;#149;Age &amp;#062; 18 years of age
&amp;#149;Albumin, Bilirubin, Creatinine and INR (used to calculate MELD and Child Class) lab result date within 6 months prior to consent OR up to 2 weeks after consent
&amp;#149;Ultrasound or other imaging within 6 months prior to consent OR up to 2 weeks after consent showing no liver mass
&amp;#149;Diagnosis of cirrhosis based one or more of the following:
oHistology
oUS, MRI or CT showing cirrhotic appearing liver with splenomegaly and platelet count
of &amp;#060; 120 mm-3 
oElastography, done by ultrasound or MRI showing a cirrhotic liver
oA FibroTest result of F4 (stage 4), indicating cirrhosis 
oVarices on endoscopy or an abdominal imaging test AND presence of chronic liver disease
&amp;#149;MELD &amp;#060; 15 OR INR is &amp;#060; 1.5, Total Bilirubin is &amp;#060; 1.7 and patient has a history of intrinsic renal disease

Exclusion Criteria
&amp;#149;Clinical evidence of significant hepatic decompensation
oRefractory ascites
oGrade 3-4 encephalopathy
oHepatorenal syndrome
oChild Class C
&amp;#149;Listed for liver transplantation and noted for an “exception”
&amp;#149;Known AIDS related diseases
&amp;#149;Detection of HCC at initial evaluation
&amp;#149;Significant co-morbid medical conditions with life expectancy less than one year
&amp;#149;Cancer history within the last 5 years (excluding non-melanoma skin cancer)
&amp;#149;Need for long-term immunosuppressive therapy for solid organ transplant
&amp;#149;Prior solid organ transplant

&lt;/value&gt;&lt;recordNumber&gt;422&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;423&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hepatocellular carcinoma Early Detection Strategy study&lt;/value&gt;&lt;recordNumber&gt;424&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Cases eligibility:
- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

   - No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last    5 years

   - Blood collected prior to treatment (chemo/radiation)

Controls eligibility
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an “other cancer” control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate) – Set C only 37 other cancers.

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status, and PKY history of smoking
&lt;/value&gt;&lt;recordNumber&gt;425&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;426&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set C Application: Rachel Ostroff - SomaLogics (2010)&lt;/value&gt;&lt;recordNumber&gt;427&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;To-date, through the efforts of Co-Investigator Dr. John Wei in the Department of Urology, the University of Michigan EDRN has procured serum, plasma and urine from &amp;#062;1000 men referred to Dr. Wei with an indication for prostate biopsy. Of these, only 37.5% exhibit malignant glands on one or more needle biopsies. This is perhaps not surprising, as the majority (70%) of men referred for needle biopsy exhibit pre-biopsy PSA values of &amp;#060;10ng/ml, which, as described above, are not diagnostic for PCa. Taken together, these studies show that low serum PSA and other recently developed biomarkers cannot reliably distinguish between PCa and BPH or indicate which patients should, or should not, undergo diagnostic needle biopsy. Therefore, it is desirable to develop
and validate suitable biomarkers that could be used alone or in conjunction with PSA to distinguish patients at high risk for PCa who should undergo diagnostic needle biopsy from those
at low risk who could benefit from watchful waiting. &lt;/value&gt;&lt;recordNumber&gt;428&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;STUDY DESIGN
1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers to distinguish between patients at high-risk versus low-risk for harboring prostate malignancies. However, this pilot and feasibility study utilized a very small sample size of 51 patients, which limited the ability of this study to adequately assess certain technical aspects of the ELISA technique and statistical aspects of  we propose studies designed assess the robustness (Specific Aim 1) and predictive value (Specific Aim 2) of these markers in a larger study population.
2. ELISA Assays. Serum, plasma, or urine chemokine levels are assessed using 50 ul frozen specimen per sandwich ELISA in duplicate using the appropriate commercially-available capture antibodies, detection antibodies, and standard ELISA reagents (R&amp;D Systems), as we have described previously (15, 17, 18). Measures within each patient group are regarded as biological replicates and permit statistical comparisons between groups. For all ELISAs, a standard curve is generated with the provided standards and utilized to calculate the quantity of chemokine in the sample tested. These assays provide measures of protein concentration with excellent reproducibility, with replicate measures characterized by standard deviations from the mean on the order of &amp;#060;3%.
&lt;/value&gt;&lt;recordNumber&gt;429&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Chemokine Prostate Cancer Biomarkers&lt;/value&gt;&lt;recordNumber&gt;430&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Sample Eligibility defined in DCP Protocol&lt;/value&gt;&lt;recordNumber&gt;431&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;432&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Full Reference Set Application :Timothy Block - Drexel Univ (2010)&lt;/value&gt;&lt;recordNumber&gt;433&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;5.2   Eligibility 
5.2.1    Inclusion Criteria
&amp;#149;   Adults 50-80 and undergoing a colonoscopy defined as:
o   First time screening or a surveillance procedure  
o   No complete colon exam (colonoscopy or CT colonography) within 3 years except as noted. (see section 5.4.1)  
&amp;#149;   Willing to sign informed consent 
&amp;#149;   Able to physically tolerate removal of up to 50 ml of blood
&amp;#149;   Willing to collect 2 stool samples 
&amp;#149;   Willing to collect 150 ml of urine

5.2.2   Exclusion Criteria
&amp;#149;   Inability to provide informed consent
&amp;#149;   History of Inflammatory Bowel Disease
&amp;#149;   Overt rectal bleeding within (including due to suspected hemorrhoids).
&amp;#149;   Positive guiaic-based occult blood or fecal immunochemical test (e.g. FOBT, FIT) in the past 12 months.
&amp;#149;   Undergone resection of the colon for any indication
&amp;#149;   Subjects with known HIV or chronic viral hepatitis (Hepatitis B and C)
&amp;#149;   Subjects with known or suspected HNPCC (Lynch Syndrome) or FAP
&amp;#149;   Any cancer  within 5 years of enrollment except any of the following: 
o   Squamous cell carcinoma of the skin or Basal cell carcinoma of the skin
o   Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only.  (Excluded if had pelvic radiation) 
o   Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery
&lt;/value&gt;&lt;recordNumber&gt;434&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;435&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Biomarkers for the Early Detection of Colorectal Adenocarcinoma (GLNE 010)&lt;/value&gt;&lt;recordNumber&gt;436&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Lung Set A description&lt;/value&gt;&lt;recordNumber&gt;437&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;438&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set A Application: LaszloTakacs - Biosystems (2010)&lt;/value&gt;&lt;recordNumber&gt;439&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;&lt;recordNumber&gt;440&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;441&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application ( #2): Lubman - Univ of Michigan (2010)&lt;/value&gt;&lt;recordNumber&gt;442&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see cancer in women reference set description&lt;/value&gt;&lt;recordNumber&gt;443&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;444&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: James Morre - NOX Technologies Inc. (2009)&lt;/value&gt;&lt;recordNumber&gt;445&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;446&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;447&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;US-Turkey Cappadocia Mesothelioma Project&lt;/value&gt;&lt;recordNumber&gt;448&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;&lt;recordNumber&gt;449&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;450&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Hiro Yamada - Wako (2011)&lt;/value&gt;&lt;recordNumber&gt;451&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;452&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;453&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application (#1): Laura Beretta-FHCRC (2011)&lt;/value&gt;&lt;recordNumber&gt;454&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;455&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;456&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Kevin Qu-Quest (2011)&lt;/value&gt;&lt;recordNumber&gt;457&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Criteria for Sensitivity and Specificity
Specificity for first line blood test set at 98% from following considerations:
1. Annual incidence in postmenopausal women ~ 1 in 2,500
2. Minimum criterion for screening for OC to be acceptable: 1 OC in 10 study
indicated surgeries
3. Target criterion: 1 OC in 5 surgeries
4. Requires 500 fold improvement in “incidence” of OC
5. Screening trials show TVS reduces false positive rate by 10X amongst subjects
with a positive CA125 test (absolute or longitudinal)
6. 500 fold achieved by 50 fold (blood test) x 10 fold (TVS) = 500
7. First line blood test needs to achieve a 50 fold increase in incidence – therefore
set specificity at 98% (50 fold), maximize sensitivity.
Sensitivity set to at least 5% (at 98% specificity)
8. Perspective is that 5-6 blood biomarkers may form a panel that covers most
ovarian cancers
9. Biomarkers with less than 5% sensitivity unlikely to contribute much sensitivity to
a panel of 6 biomarkers
10. Ideally, new biomarkers will:
a. identify OC not identified by CA125, or
b. identify OC earlier than CA125 (or best – both)
11. Less ideally, but nonetheless helpful, will be biomarkers that identify OC also
identified by CA125, and at the same time. These biomarkers will contribute
information on the presence of OC in situations where the CA125 signal is weak
to moderate, if the variation of the new biomarker and CA125 in control subjects
is independent. (CA125 and the new biomarker values are dependent in OC
cases, as the tumor presence will increase both of them).&lt;/value&gt;&lt;recordNumber&gt;458&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Early detection of Ovarian Cancer (OC) is one of the key clinical problems in this 
disease. We propose a team EDRN project to address the issue of early detection of 
OC by performing a validation study on candidate protein markers already identified in 
previous EDRN research or in the literature (e.g. protein products of TCGA identified 
mutations specific to ovarian cancer). (See appendix for full listing) Biospecimen 
sources have been identified which include samples obtained at diagnosis and matched 
controls (Urban, Godwin, Marks, Skates), and longitudinal samples obtained prior to 
diagnosis (Urban, Skates, Godwin). Bioinformatic filters will be applied to rank the 
candidates (Diamandis). In order of ranking, candidate proteins for which high quality 
antibodies are available will be measured by development of ELISAs at JHU 
(Chan/Zhang) or through NAPPA at DFCI (Anderson/LaBaer), while for other 
candidates mass spectrometry based selective reaction monitoring (SRM) assays will 
be developed at PNNL (Rodland). Three milestones are defined. The first two 
milestones are to assemble the necessary specimens and to develop the qualifying 
assay(s). The final milestone is to estimate the markers’ sensitivity one year prior to 
diagnosis at a given high specificity.&lt;/value&gt;&lt;recordNumber&gt;459&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Early Detection Ovarian Cancer Biomarkers (Team Project)&lt;/value&gt;&lt;recordNumber&gt;460&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Identification of eligible subjects:
Each participating CVC will utilize a registry of women who have had breast surgery for benign breast disease at the CVC hospital/cancer center in the time period 1 January 1994 through 31 December 2004.  Cases of atypical ductal hyperplasia (ADH) that meet the inclusion-exclusion criteria will be given a unique EDRN-VSIMS number. 
Study Cohort Inclusion Criteria:
1.Diagnosis of BBD with atypia (ADH).
2.Formalin-fixed archival tissue (preferably excisional biopsy or core biopsy) sufficient for 2 or more tissue sections.
3.Adequate follow-up information to determine subsequent cancer status (IBC yes-no).
4.Clinical information sufficient to determine race, family history of breast cancer, mammography history and breast surgery history, and clinical management and outcome of patients developing IBC.
Study Cohort Exclusion Criteria:
1.Women age &amp;#060; 40 or &amp;#062; 70 at the time of first BBD breast biopsy.
2.Women with diagnosed concurrent invasive breast cancer, DCIS, invasive lobular carcinoma or lobular carcinoma in situ.
3.Women with insufficient clinical information to determine subsequent breast health history including mammography status and invasive breast carcinoma.
4.Women who had only FNA or in whom the pathology bloc contains insufficient material for at least two cut sections.
 
&lt;/value&gt;&lt;recordNumber&gt;461&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;462&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Benign Breast Disease Team Project&lt;/value&gt;&lt;recordNumber&gt;463&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Cases: Women diagnosed with TNBC 
Controls: Women diagnosed with non-proliferative benign breast disease&lt;/value&gt;&lt;recordNumber&gt;464&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;465&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Triple Negative Breast Cancer Team Project&lt;/value&gt;&lt;recordNumber&gt;466&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;467&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;468&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Full Reference Set Application: Hiro Yamada - Wako (2011)&lt;/value&gt;&lt;recordNumber&gt;469&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Since several different studies are involved, multiple eligibility criteria exist.&lt;/value&gt;&lt;recordNumber&gt;470&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Our goal is to discover plasma and tissue-based tumor biomarkers that work well enough together to identity colon cancer at early stages, lead to accurate diagnosis and could ultimately allow for individualized treatment.&lt;/value&gt;&lt;recordNumber&gt;471&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Affinity-based strategies to fast track development of colon cancer biomarkers&lt;/value&gt;&lt;recordNumber&gt;472&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;473&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;474&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Full Reference Set Application: David Lubman - Univ of Michigan (2011)&lt;/value&gt;&lt;recordNumber&gt;475&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1. Ovarian serous disease (benign or malignant) with cyst for cyst fluid extraction, age &amp;#062; 21
2 &amp; 3. ovarian serous cancer tissue, or normal fallopian tube tissue, age &amp;#062; 21
&lt;/value&gt;&lt;recordNumber&gt;476&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Discovery and verification of early detection ovarian cancer plasma/serum biomarkers.&lt;/value&gt;&lt;recordNumber&gt;477&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Genetic and Longitudinal Pathways to Ovarian Cancer Biomarkers&lt;/value&gt;&lt;recordNumber&gt;478&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Lung Set A&lt;/value&gt;&lt;recordNumber&gt;479&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;480&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set A Application: Dawn Coverley- University of York (2011)&lt;/value&gt;&lt;recordNumber&gt;481&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;5.5   Eligibility
5.5.1   Inclusion Criteria
18 years of age or older
Meet any one of the following criteria from the international consensus guidelines for resection26:
&amp;#149;   Symptomatic from their pancreatic cyst
&amp;#149;   Side branch cyst along with main duct involvement (mixed main duct- side branch IPMN)
&amp;#149;   Presence of mural nodules in cyst
&amp;#149;   At least one cyst greater than 3 cm in size
&amp;#149;   Surgeon decided to remove cyst
&amp;#149;   At least 4ml of Serum, 2ml of Plasma AND a minimum of 1ml of Cystic Fluid obtained by EUS or by surgery or preferably by both options
&amp;#149;   Blood collected w/in 12 weeks prior to Surgery

5.5.2   Exclusion Criteria
&amp;#149;   Prior Pancreatic Cancer
&amp;#149;   Prior Pancreatic Surgery
&amp;#149;   Prior history of any other malignancy except non-melanoma skin cancers for five years (Disease free for 5 years)
&lt;/value&gt;&lt;recordNumber&gt;482&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;483&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Cystic Fluid Reference Set&lt;/value&gt;&lt;recordNumber&gt;484&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;485&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;486&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers for the Early Detection of Pancreatic Cancer&lt;/value&gt;&lt;recordNumber&gt;487&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;488&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;489&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application (#2): Laura Beretta-FHCRC (2011)&lt;/value&gt;&lt;recordNumber&gt;490&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All study participants must be 18 years of age or older, able to physically tolerate removal of 30 – 60 ml of blood and willing to sign informed consent.  
   The criteria to be a healthy control are 1) no prior history of any other malignancy except non-melanoma skin cancers for the past ten years, 2) no personal history of colonic polyps, ulcerative colitis or crohn’s disease, and 3)    Normal colonoscopy with excellent or good colonic preparation within 2 years. 
   Adenomatous polyps patients will be defined as a colorectal polyp meeting histological criteria for adenomatous polyp that does not meet criteria for an advanced adenoma.
   Advanced adenomatous polyps will be defined as adenoma with significant villous features (&amp;#062;25%), size of 1.0 cm or more, high-grade dysplasia, or early invasive cancer
   Stage A/B colorectal cancer patients will be defined as any T, N0, and M0.  The patient must not have started any form of cancer treatment at the time of sample collection.
   Stage C/D colorectal cancer patients will be defined any T, N &amp;#062; 1, and any M.  The patient must not have started any form of cancer treatment at the time of sample collection.
&lt;/value&gt;&lt;recordNumber&gt;491&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;492&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Preliminary Validation of Biomarkers for the Detection of Colorectal Adenomas (Team Project #1)&lt;/value&gt;&lt;recordNumber&gt;493&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All patients will have, at baseline, one or more non-advanced or advanced adenoma.  Because the number and histology of the baseline adenomas will influence the scheduling of subsequent colonoscopies, the number and histology of adenomas (and, potentially, their interaction) and the time to subsequent screen will be used as covariates in all modeling.  &lt;/value&gt;&lt;recordNumber&gt;494&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;495&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers of Risk for Colorectal Neoplasia (Team Project #2)&lt;/value&gt;&lt;recordNumber&gt;496&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW protocol&lt;/value&gt;&lt;recordNumber&gt;497&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;498&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: GeorgeTuszynski - Temple University (2012)&lt;/value&gt;&lt;recordNumber&gt;499&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see breast reference set protocol&lt;/value&gt;&lt;recordNumber&gt;500&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;501&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application:  Anu Mathew-Meso Scale (2012)&lt;/value&gt;&lt;recordNumber&gt;502&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;C.   Exclusions
Exclusion criteria for the underlying cohort of DCIS patients
&amp;#149;   Women with a prior history of in situ or invasive breast cancer. 
&amp;#149;   Age &amp;#8805;80 years at the time of DCIS diagnosis.
&amp;#149;   Age &amp;#8804;29 years at the time of DCIS diagnosis.
Exclusion criteria for selection into the nested case-control study
&amp;#149;   Women without formalin-fixed archival tissue.
&amp;#149;   Women diagnosed with a cancer other than breast cancer between DCIS diagnosis and IBC (excluding non-melanoma skin cancers and in situ cervical cancers).
&amp;#149;   Women who underwent a bilateral mastectomy to treat their first primary DCIS (because these women have a markedly lower risk of developing IBC).

 
D.   Case Selection 
Cases are defined as subjects who are diagnosed with IBC &amp;#8805;6 months after DCIS diagnosis. Diagnoses of IBC will be confirmed through state/regional cancer registries, institutional cancer registries, or medical record reviews. Clinical information will be obtained (see below) and subjects will be dropped if they meet any of the exclusion criteria. Slides will be obtained to make sure the subject is appropriate and has enough tissue.

E.   Control Selection
Controls will be randomly selected from the underlying DCIS cohort and matched 2:1 to the cases on age at DCIS diagnosis (exact age), year of DCIS diagnosis (exact year), survival for a duration after diagnosis at least equivalent to the interval between the corresponding case’s 1st and 2nd primary diagnoses (to the month, so that they have an equal amount of time at risk), surgical treatment (in the following categories: biopsy only, lumpectomy without nodal dissection, lumpectomy with nodal dissection, and mastectomy), and radiation treatment (yes vs. no). Controls must also be known to not have been diagnosed with invasive breast cancer&lt;/value&gt;&lt;recordNumber&gt;503&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Both overtreatment and undertreatment of DCIS are pervasive problems given that no useful approaches for identifying which DCIS patients are likely or highly unlikely to go on to develop invasive breast cancer are currently available. The identification of useful markers could have considerable clinical impact in guiding both treatment and follow-up decision making.&lt;/value&gt;&lt;recordNumber&gt;504&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;DCIS Team Project&lt;/value&gt;&lt;recordNumber&gt;505&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Same as for Pancreatic Reference Set
3.1   Cases  (Pancreatic Cancer) 
Patients will be consented prior to surgery.   
A.  No prior history of any other malignancy except nonmelanoma skin cancers for ten years.
B.  Must have undergone complete surgical resection of the tumor with curative intent including the presence of negative margins and a pathologic staging of I or IIA.
C.  Must have histological verification of a pancreatic adenocarcinoma 
D.  Must not have received preoperative chemoradiation (neoadjuvant) therapy due to our inability to adequately stage these patients. 
E.  Able to give informed consent. 
F.  Blood sample must be obtained within the past 2 weeks prior to surgery/anesthesia according to procedure described in Appendix D.  

Post-Enrollment Criteria: Inclusion of the patient in the proposed validation set is dependent on the results of the surgery. The patient must have undergone complete surgical resection of the tumor with curative intent including the presence of negative margins and a pathologic staging of I or IIA. Samples from any patients not meeting these criteria will be used in a discovery set. 
3.2   Controls
Three different control groups are proposed for this reference set: chronic pancreatitis patients, acute benign biliary obstruction patients and healthy controls. The cases and controls are required to have a similar age distribution. Although we will attempt to keep the same number of cases and controls within each site (1 to 3 ratio), age distribution does not have to be similar for cases and controls within each site.  An algorithm developed by Feng and colleagues will be used to recruit cases and controls across multi-centers to ensure that the cases and controls are frequency matched by age. Eligibility criteria for each of the controls groups are described below. Control specimens will not be collected until 10 post-operative PC cases have been successfully enrolled in the study. &lt;/value&gt;&lt;recordNumber&gt;506&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;507&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application: Brian Haab-Van Andel  (2012)&lt;/value&gt;&lt;recordNumber&gt;508&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;509&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;510&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Upgrading Team Project&lt;/value&gt;&lt;recordNumber&gt;511&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;5.2.1   Inclusion Criteria
&amp;#149;   Greater than or equal to 45 years of age
&amp;#149;   &amp;#062;20 pack-years of smoking
&amp;#149;   Presenting for the evaluation of pulmonary nodules 7mm-25mm in diameter seen on chest CT
5.2.2   Exclusion Criteria
&amp;#149;   Pure ground glass opacities on CT chest
&amp;#149;   Established lung cancer diagnosis
&amp;#149;   Contraindications to nasal brushings or fiberoptic bronchoscopy
o   Including ulcerative nasal disease
o   Hemodynamic instability
o   Severe obstructive airway disease
o   Unstable cardiac or pulmonary disease
o   Inability to protect airway or altered level of consciousness
&amp;#149;   Inability to provide informed consent
&lt;/value&gt;&lt;recordNumber&gt;512&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;513&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)&lt;/value&gt;&lt;recordNumber&gt;514&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see breast ref set protocol&lt;/value&gt;&lt;recordNumber&gt;515&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;516&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Richard Zangar-PNNL (2012)&lt;/value&gt;&lt;recordNumber&gt;517&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;518&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;519&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Gary Norman-INOVA (2012)&lt;/value&gt;&lt;recordNumber&gt;520&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;521&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Study Overview. We will examine DNA extracted from FFPE sections from approximately 200 different surgically resected primary pancreatic tumors from the UNMC Department of Pathology and
Microbiology. DNA will be purified from those sections and subjected to deep sequencing for the entire TP53 locus.
Expected Outcomes
We expect to find a difference in the p53 mutation status between tumor samples from patients that ultimately experienced tumor recurrence (more aggressive) compared to those that did not. Parallel studies to develop ICP will enable us to rapidly develop a low cost platform to extend these studies to larger patient populations for future validation studies.
Future Studies
The experiments proposed in this application represent a state-of-the-art approach to identify molecular markers that will help clinicians to ascertain the tumor recurrence risk for their pancreatic cancer patients who have undergone a Whipple procedure. If our initial studies support the hypothesis that p53 mutations are associated with early metastasis of pancreatic cancer, these studies would be extended to other cohorts of patient samples that are available at other major centers that see pancreatic cancer patients. Development of ICE COLD-PCR platforms to screen for these mutations will facilitate a reliable, rapid and low cost method for predicting tumor aggressiveness in these patients, which will be deployed in future studies should the hypothesis be supported.&lt;/value&gt;&lt;recordNumber&gt;522&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hollingsworth - Aggressive vs Indolent 2012&lt;/value&gt;&lt;recordNumber&gt;523&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Because lung cancer occurs in both males and females and members of all ethnic groups, clinical specimens
from both sexes and a variety of ethnic groups will be utilized in the proposed studies. Human clinical
specimens of normal, premalignant, and malignant lung tissue utilized in Aim 1 are available through the UCLA
Lung Cancer SPORE Tissue Repository. The specimen bank includes males, females, and members of
ethnically/racially diverse groups. Research in this proposal will utilize existing specimens in the tissue
repository, so it will not be necessary to recruit new subjects for the research in this proposal. The approximate
composition of the tissue repository is described in the Table 2.
African Americans 5
Hispanic/Latino 1
Asian Americans 5
Native Americans0
Pacific Islanders 0
White 29
Other 0
Total 40
&lt;/value&gt;&lt;recordNumber&gt;524&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;525&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Dubinett - Targeted Sequencing 2012&lt;/value&gt;&lt;recordNumber&gt;526&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Create repository with DNA samples extracted from normal tissue, BE, BE+LGD, BE+HGD,
and EAC&lt;/value&gt;&lt;recordNumber&gt;527&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;528&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Using the methylome to identify aggressive Barrett’s esophagus&lt;/value&gt;&lt;recordNumber&gt;529&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.”&lt;/value&gt;&lt;recordNumber&gt;530&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;531&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers&lt;/value&gt;&lt;recordNumber&gt;532&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The first enrolled 1,907 breast cancer patients diagnosed between 55-74 years of age from 2000-2008,
and the other enrolled 1,028 younger women 20-44 years of age diagnosed from 2004-2010. Details regarding
the methods of both studies have been published.21,22 For this pilot study we propose to limit eligible cases to
the 321 Group Health Cooperative (GHC, a large integrated health organization serving western Washington
state) patients who underwent mammographic screening and were diagnosed between 40-74 years of age (so
that it is restricted to women for whom screening mammography may be recommended) with stage I or II
breast cancer. The study is restricted to women with stage I or II disease in order to make the patients uniform
with respect to stage, and because an appreciable majority of screen detected tumors diagnosed among
women in this age range are early stage.&lt;/value&gt;&lt;recordNumber&gt;533&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Distinguishing aggressive cancers from non-aggressive or non-progressing cancers is an issue of both clinical
and public health importance particularly for those cancers with an available screening test. With respect to
breast cancer, mammographic screening has been shown in randomized trials to reduce breast cancer
mortality, but given the limitations of its sensitivity and specificity some breast cancers are missed by
screening. These so called interval detected breast cancers diagnosed between regular screenings are known
to have a more aggressive clinical profile. In addition, of those cancers detected by mammography some are
indolent while others are more likely to recur despite treatment. The pilot study proposed herein is highly
responsive to the EDRN supplement titled “Biomarkers to Distinguish Aggressive Cancers from Nonaggressive
or Non-progressing Cancers” in that it addresses both of the research objectives related to these
issues outlined in the notice for this supplement:
Aim 1: To identify biomarkers in tumor tissue related to risk of interval detected vs. mammography
screen detected breast cancer focusing on early stage invasive disease. We will compare gene
expression profiles using the whole genome-cDNA-mediated Annealing, Selection, extension and Ligation
(DASL) assay of 50 screen detected cancers to those of 50 interval detected cancers. Through this approach
we will advance our understanding of the molecular characteristics of interval vs. screen detected breast
cancers and discover novel biomarkers that distinguish between them.
Aim 2: To identify biomarkers in tumor tissue related to risk of cancer recurrence among patients with
screen detected early stage invasive breast cancer. Using the DASL assay we will compare gene
expression profiles from screen detected early stage breast cancer that either recurred within five years or
never recurred within five years. These two groups of patients will be matched on multiple factors including
tumor stage and treatments received. Our goal with this comparison is to identify novel biomarkers that
discriminate between tumors that recur and are more aggressive compared to those that are less aggressive
and do not recur.
This project will evaluate well characterized tumor tissue specimens using a robust high dimensional laboratory
approach and generate preliminary data that will motivate a larger scale study of high translational relevance.&lt;/value&gt;&lt;recordNumber&gt;534&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer&lt;/value&gt;&lt;recordNumber&gt;535&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;this proposal will provide for comprehensive profiling of DNA methylation across the promoter
associated CpG islands of 20 matched pairs (40 samples) of colon cancer hepatic metastasis and matched colon cancer primary tumors.&lt;/value&gt;&lt;recordNumber&gt;536&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;537&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Targeted Sequencing for Discovery and Validation of DNA Methylation Markers of Colon Cancer Metastasis&lt;/value&gt;&lt;recordNumber&gt;538&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;364&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Active Surveilance men with an expected outcome or a disastrous outcome.&lt;/value&gt;&lt;recordNumber&gt;539&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;364&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The Early Detection Research Network of the NCI is charged with the discovery, development and
validation of biomarkers for early detection and prognosis related to neoplastic disease. Our laboratory is an NCI EDRN (U01CA152813) working  on &amp;quot;Glycoprotein biomarkers for the early detection of aggressive prostate cancer&amp;quot;.  This EDRN administratiVE! supplement is a collaboration with Robert  Veltri on his project
to identify men with very low risk (indolent) prostate cancer (CaP) at the diagnostic biopsy at selection for
active surveillance (AS). We will assess biopsy tissue using quantitative nuclear histomorphometric measurements and molecular biomarkers to predict an unexpected catastrophic CaP in such men with indolent CaP. At Johns Hopkins Hospital w1e use the Epstein criteria that includes; PSA density  (PSAD)
&amp;#060;0.15 ng/mVcm3, Gleason score SS, S2 cons involved with cancer, and ::;;SO% of any core involved with
cancer  to select AS.  Our approach will study 140 AS men (70 with a expected outcome and 70 with a disastrous outcome) using nuclear histomorphometry and pre-qualified biomarkers quantified by digital microscopy.  Previously, our laboratory combined measurements of DNA content  and (-2)pPSA in the serum and (-5,-?)pPSA in biopsy tissue to identify 7/10  men that would fail surveillance based on the primary diagnostic biopsy. We now will devHiop a clinical, morphological and biomarker &amp;#39;signature&amp;#39; for identifying severe aggressive disease from a AS diagnostic biopsy. Our approach will combine nuclear morphometry measured by digital microscopy with a unique biopsy  tissue biomarker profile  (DNA content, Ki67, Her2neu, CACND1 and periostin). Fc&amp;#149;r the molecular targets we will us&amp;#149;e a multiplex tissue blot (MTB) immunohistochemistry method. The Aims o&amp;#39;f our work include 1) to utilize retrospective archival biopsy
material from 70 AS cases where the outcome was unexpected and disastrous and collect an equal number of AS cases (n=140) and perform assays for morphology and biomarker targi  ts proposed, 2) and predict
failure  using Cox proportional hazards statistical modeling.
&lt;/value&gt;&lt;recordNumber&gt;540&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;364&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;541&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;366&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Pancreatic Cancer Reference Set Description&lt;/value&gt;&lt;recordNumber&gt;542&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;366&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;543&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;366&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application- Ann Killary and Subrata Sen-MD Anderson (2012)&lt;/value&gt;&lt;recordNumber&gt;544&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;367&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Breast Ref Set&lt;/value&gt;&lt;recordNumber&gt;545&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;367&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;546&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;367&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: GeorgeTuszynski-Temple (2012)&lt;/value&gt;&lt;recordNumber&gt;547&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;368&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Same as PASS cohort&lt;/value&gt;&lt;recordNumber&gt;548&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;368&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;549&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;368&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Lin UW (2010) TMPRSS2-ERG-PCA-PASS&lt;/value&gt;&lt;recordNumber&gt;550&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;369&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;551&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;369&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;552&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;369&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Using MALDI-IMS and MRM to stablish a pipeline for discovery and validation of tumor neovasculature biomarker candidates.&lt;/value&gt;&lt;recordNumber&gt;553&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;370&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;554&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;370&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;555&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;370&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers&lt;/value&gt;&lt;recordNumber&gt;556&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;371&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Women in the WHI Observational Study with an available plasma sample drawn &lt;/value&gt;&lt;recordNumber&gt;557&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;371&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;558&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;371&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Breast and Ovary Cancer CVC, Study 1: Preliminary validation of breast cancer early detection biomarker candidates from our WHI discovery project&lt;/value&gt;&lt;recordNumber&gt;559&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;372&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All women in PLCO trial were considered eligible.  &lt;/value&gt;&lt;recordNumber&gt;560&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;372&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Over 70% of women with ovarian/fallopian tube cancer (OC) are diagnosed with advanced stage disease which has a 5-year relative survival rate of 30%. Five-year survival is 90% when disease is confined to the ovaries, but overall survival is poor because only 25% of cases are found early. Screening for ovarian cancer using tools with high sensitivity is potentially cost-effective, but because OC is so rare, very high specificity is needed to achieve an acceptable PPV.  We have conducted preliminary work both in clinical and in preclinical (CARET) samples. We have identified candidate markers, developed assays for novel markers including HE4 and MSLN, and evaluated their diagnostic performance.  We evaluated the markers’ contribution to a diagnostic panel in a standard set in order to identify the best of the candidates and developed methods for combining markers to define a decision rule for a marker panel. We found that our PEB rule yields comparable performance to the Single Threshold (ST) rule 2 years earlier, using the same two markers. The PEB makes an even larger contribution with the 4-marker panel.  The 4-marker panel with the PEB rule represents a substantial improvement over any of the other decision rules as a first-line screen to select women for imaging. Our goal in the proposed work is to estimate the improvement in performance possible in the PLCO serial samples.&lt;/value&gt;&lt;recordNumber&gt;561&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;372&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Breast and Ovary Cancer CVC, Study 2: Phase 3 retrospective validation of ovarian cancer early detection markers in serial preclinical samples from the PLCO trial&lt;/value&gt;&lt;recordNumber&gt;562&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;373&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All women in PLCO trial screening arm were considered eligible if they had no prior bilateral salpingo-oophorectomy (BSO) at the time of enrollment.&lt;/value&gt;&lt;recordNumber&gt;563&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;373&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;We will collaborate with investigators from University College London to test a screening decision rule in preclinical serial samples from the U.K. Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) to learn if the panel can do better than CA125 alone. The UKCTOCS is an ideal setting for retrospective validation of an early detection marker panel and decision rule because it offers serial samples collected annually and use of imaging in women with rising CA125. Multi-modal strategies using serum markers HE4, MSLN, MMP7, and CA125 will be compared to strategies relying exclusively on CA125 and transvaginal sonography (TVS).&lt;/value&gt;&lt;recordNumber&gt;564&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;373&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Breast and Ovary Cancer CVC, Study 3: Phase 3 Validation of screening decision rules in preclinical UKCTOCS serial samples&lt;/value&gt;&lt;recordNumber&gt;565&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;374&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;No prior epithelial ovarian cancer and no bilateral salpingo-oophorectomy (BSO) at time of enrollment.  &lt;/value&gt;&lt;recordNumber&gt;566&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;374&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The WHI offers an opportunity to evaluate ovarian cancer markers and screening decision rules developed and validated in EDRN CVC Studies 2 and 3 in women who were not being screened. It is particularly well suited to validation of risk markers, since many serum samples were drawn well before clinical diagnosis of cancer in the WHI cohorts. A strategy is needed to identify from among the general population of women over the age of 50 those at high-risk for a diagnosis of ovarian/fallopian tube cancer so that they can be referred for appropriate surveillance, imaging or surgical consult. Tools to identify high-risk women will be investigated including serum markers CA125, HE4, MSLN, and MMP7 and epidemiologic risk factors. We will optimize decision rules using stored serum samples from the WHI OS and conduct a simulated prospective validation using stored serum samples from the WHI CT. Decision rules to select women for ovarian cancer screening will be investigated as well as decision rules for use in ovarian cancer screening.&lt;/value&gt;&lt;recordNumber&gt;567&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;374&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Breast and Ovary Cancer CVC, Study 4: Phase 3 Validation of Ovarian Cancer Serum Markers in Preclinical WHI Samples&lt;/value&gt;&lt;recordNumber&gt;568&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;375&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;569&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;375&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;570&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;375&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Study 5:  Phase 2 and 3 Validations of Putative Breast Cancer Early Detection Candidates&lt;/value&gt;&lt;recordNumber&gt;571&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;376&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion
&amp;#149;   Males greater than or equal to age 18
&amp;#149;   Patient scheduled for prostate biopsy for any of the following reasons:
o   PSA &amp;#062;2.0 ng/ml
o   Elevated PSA velocity (&amp;#062;0.4 ng/ml/yr)
o   Lower PSA value with other risk factors for PCa (e.g.; family history)
o   Prior ASAP or HGPIN
o   Abnormal DRE
o   % free PSA &amp;#060;15%
&amp;#149;   Finasteride/dutasteride and other medications for BPH and ED are allowable but will be recorded 
Exclusion
&amp;#149;   History of PCa
&amp;#149;   Urine not collected post DRE prior to index prostate biopsy
o   Blood can be collected up to 1 month before urine
o   Urine can be collected up to 1 month before index biopsy
&amp;#149;   Index prostate biopsy with &amp;#060;10 cores and without extended template
&amp;#149;   Index prostate biopsy pathology report unavailable
&amp;#149;   Participating in an intervention trial for prostate disease
&amp;#149;   Prior surgical (open or endoscopic) or minimally invasive treatment (TUNA/TUMT) for BPH
&amp;#149;   Prior saturation biopsy defined as at least 30 cores
&amp;#149;   Prior prostate biopsy within 6 months
&amp;#149;   Prior PCA3 test performed for clinical purpose
&amp;#149;   Consented more than 3 months before index biopsy
&lt;/value&gt;&lt;recordNumber&gt;572&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;376&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;We hypothesize that combining T2:erg (T2:erg) fusion and PCA3 detection in urine collected after digital rectal exam can improve the specificity of identifying clinically significant  prostate cancer presence over the standard PSA and DRE.  To address this hypothesis we propose to validate the performance of the urinary T2:erg in a multiplex model predicting the diagnosis of clinically significant  prostate cancer on subsequent prostate biopsy using post-DRE pre biopsy urine specimens from a cohort of 900 men on the EDRN’s PCA3 trial.&lt;/value&gt;&lt;recordNumber&gt;573&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;376&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014)&lt;/value&gt;&lt;recordNumber&gt;574&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;377&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion criteria. This is an observational clinical trial. Adult male patients, around the ages of 45 to 75
years old are eligible to be recruited into this trial if:
1. They have been advised to have and agreed to a prostate biopsy;
2. They have completed all premedication requirements to have a biopsy;
3. They have completed the clinical biopsy procedure of providing 12-tissue cores;
4. They have completed a fully executed IRB-approved informed consent.
Exclusion criteria.
None. The clinical criteria for recommending a clinical biopsy for suspected prostate cancer are self defining of the eligible and ineligible population.&lt;/value&gt;&lt;recordNumber&gt;575&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;377&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;To develop a multi-site prospective clinical validation trial of the multigene diagnostic signature for the diagnosis of prostate cancer from non tumor containing biopsy tissue. Prostate cancer now affects one in five men in the U.S. It is diagnosed by  examination of a biopsy sample of the prostate gland by a pathologist and treatment decisions such as the choice of surgery are usually not made without direct visualization of the presence of cancer by a pathologist. There are about one million such biopsy procedures in the U.S. every year. However about 1-200,000 are ambiguous owing to the absence of tumor but the presence of small changes such as atypical small acinar proliferations (ASAP) or proliferations within otherwise normal glands (PIN, prostate  intraepithelial neoplasia) that are highly suspicious for cancer. Studies by the UCI/NCI SPECS project on prostate cancer have led to a new way to diagnosis the presence of prostate cancer in these ambiguous changes. Researchers of the UCI/NCI SPECS project observed that the tissue around a tumor called stroma has many altered gene activities that are caused by molecules secreted by the tumor cells. Indeed these studies revealed that 114 genes exhibited altered activity in stroma near tumor compared to normal stroma. These changes can be used as a “signature” to examine new samples to determine the “presence of-tumor”. Such a test has many applications. Currently ambiguous cases are asked to return for a repeat biopsy in 3 to 12 months – an agonizing period for patients during which they receive no guidance and during which any tumor may continue to grow and spread. Thus, the new test would detect tumor 3 to 12 months prior to conventional practice. This will avoid repeated biopsy procedures. Patients who are positive by the new test may consider whether immediate medical treatment or neo adjuvant treatment is appropriate. In addition the ability to detect presence-of-tumor early will avoid the necessity of waiting to have a repeat biopsy procedure. Finally the genes that undergo altered activity reveal fundamental information about how tumors alter the cellular environment.
The National Cancer Institute (NCI) program called the Early Detection Research Network (ERDN) has agreed to support the continued development of the 114 gene signature for diagnosis of prostate cancer. Under this program, the 114 gene signature will undergo a series a studies designed to validate the accuracy and reliability. The gene signature will be applied to actual biopsies of consenting patients who have an ambiguous result for the first biopsy. Patients will be drawn from UCI, and the Orange County Urology Associates. All biopsy samples of this prospective clinical trial will analyzed in the UCI CLIA-approved Molecular Genetics Laboratory to determine the presence-of-tumor – a step which will facilitate eventual FDA approval for the test. The accuracy of these results will be compared to the answers determined by a pathologist examination of the repeat biopsy samples gathered from the same patients at 3 to 12 months later. The next step will be to apply the test to formalin-fixed and paraffin-embedded biopsy samples. This is the way that patients’ biopsy material across the country is preserved as part of the patients’ medical records. Once successfully  validated, the new test can be applied to any patient who has had an “ambiguous” biopsy. The EDRN supported program will allow us to validate a new type of test for prostate cancer that will speed up diagnosis of ambiguous cases by providing early detection, provide guidance for treatment, avoid repeated biopsy procedures, and will reveal new information about the mechanisms involved in the development and
growth of prostate cancer.&lt;/value&gt;&lt;recordNumber&gt;576&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;377&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;The Prostate Tumor Microenvironment Exhibits differentially expressed Genes Useful for Diagnosis&lt;/value&gt;&lt;recordNumber&gt;577&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;378&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Samples with known invasive ductal breast carcinoma diagnosis&lt;/value&gt;&lt;recordNumber&gt;578&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;378&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;579&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;378&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Karen Abbott- University of Arkansas (2013)&lt;/value&gt;&lt;recordNumber&gt;580&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;379&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW&lt;/value&gt;&lt;recordNumber&gt;581&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;379&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;582&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;379&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Michael Birrer-Massachusetts General Hospital (2013)&lt;/value&gt;&lt;recordNumber&gt;583&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;381&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt; Inclusion Criteria
&amp;#61623;
Ability to provide informed consent
&amp;#61623;
Current or former workers at a construction
materials factory who have been monitored at
MSCChC and are covered by the insu
rance described in Law No. 16,744.
&amp;#61623;
At least a 5 year employment in an occupat
ion which is associated with the handling of
asbestos containing products
&amp;#61623;
Equal to or greater than 40 y
ears of age and under 80 years of age.
 Exclusion Criteria
&amp;#61623;
Inability to undergo therapy for mesothel
ioma if diagnosed through this protocol.
&amp;#61623;
Patients with a documented previous diagnosis/treat
ment of MM will not
be eligible for entry
into the study.
&amp;#61623;
Individuals who began working
at the company on or after Ja
nuary 1, 2000 (the year that
changes were made in masks and safety systems) will also be excluded. &lt;/value&gt;&lt;recordNumber&gt;584&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;381&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;585&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;381&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Utility of Biomarkers for Early Detection of Malignant Mesothelioma in a High-risk Population&lt;/value&gt;&lt;recordNumber&gt;586&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;382&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;A. Inclusion Criteria:
1. Prostate cancer, confirmed on prostate biopsy, within two years of scheduled radical prostatectomy.
2. Prostate cancer must be graded as Gleason 3+3 on the biopsy immediately prior to radical prostatectomy.  (Secondary eligibility will be established on central review of pathology slides, and blocks if available, at Cornell Central Pathology Laboratory to confirm eligibility.)
3. Prostate cancer may have been detected on prior biopsy as well but must not be greater than Gleason 3+3.  (Also requires Central Pathology Laboratory review.)
4. Slides must be available for Central Pathology Laboratory review on any biopsy showing prostate cancer.  FFPE Blocks may also be requested if available.
5. Patient must have selected radical prostatectomy as treatment for prostate cancer.
6. Signed informed consent.
7. Blocks and/or slides from prostate biopsy and from radical prostatectomy must be available for analysis by Central Pathology laboratory.
8. Willingness to provide long-term follow-up information regarding additional treatments and cancer status.
9. Willingness to provide blood and urine specimens prior to radical prostatectomy for placement in the EDRN Upgrading Reference Set biorepository.
10. Willingness to provide demographic and clinical information related to prostate cancer and prostate cancer risk (e.g., race/ethnicity, family history of prostate cancer).
B. Exclusion Criteria:
1. Gleason score greater than 3+3 on any prior prostate biopsy.
2. Any treatment other than radical prostatectomy planned for prostate cancer.
3. Prior treatment of the prostate with androgen deprivation, radiation, or other cytotoxic chemotherapy.
&lt;/value&gt;&lt;recordNumber&gt;587&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;382&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;588&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;382&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Upgrading Reference Set&lt;/value&gt;&lt;recordNumber&gt;589&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;383&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Breast Ref Set protocol&lt;/value&gt;&lt;recordNumber&gt;590&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;383&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;591&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;383&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Chris Li-FHCRC (2014)&lt;/value&gt;&lt;recordNumber&gt;592&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;384&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;593&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;384&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Background:  The clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools.  
Methods:  Sixty-seven biomarkers were evaluated in prediagnostic sera obtained from cases of pancreatic cancer enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).      
Results:  The panel of CA 19-9, OPN, and OPG, identified in a prior retrospective study, was not effective.  CA 19-9, CEA, NSE, bHCG, CEACAM1 and PRL were significantly altered in sera obtained from cases greater than 1 year prior to diagnosis.  Levels of CA 19-9, CA 125, CEA, PRL, and IL-8 were negatively correlated with time to diagnosis.  A training/validation study using alternate halves of the PLCO set failed to identify a biomarker panel with significantly improved performance over CA 19-9 alone.  When the entire PLCO set was used for training at a specificity (SP) of 95%, a panel of CA 19-9, CEA, and Cyfra 21-1 provided significantly elevated sensitivity (SN) levels of 32.4% and 29.7% in samples collected &amp;#060;1 and &amp;#062;1 year prior to diagnosis, respectively, compared to SN levels of 25.7% and 17.2% for CA 19-9 alone.      
Conclusions:  Most biomarkers identified in previously conducted case/control studies are ineffective in prediagnostic samples, however several biomarkers were identified as significantly altered up to 35 months prior to diagnosis.  Two newly derived biomarker combination offered some advantage of CA 19-9 alone in terms of SN, particularly in samples collected &amp;#062;1 year prior to diagnosis, however further study will be needed to fully define the implications of these findings.  
&lt;/value&gt;&lt;recordNumber&gt;594&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;384&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers for early detection of pancreatic cancer&lt;/value&gt;&lt;recordNumber&gt;595&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;385&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Breast Reference Set 1
Breast Reference Set 2 &lt;/value&gt;&lt;recordNumber&gt;596&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;385&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;597&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;385&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Karen Anderson-ASU (2014)&lt;/value&gt;&lt;recordNumber&gt;598&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;386&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;599&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;386&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;600&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;386&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application: Michael Hollingsworth-University of Nebraska (2014)&lt;/value&gt;&lt;recordNumber&gt;601&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;387&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see breast reference set protocol&lt;/value&gt;&lt;recordNumber&gt;602&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;387&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;603&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;387&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Pinku Mukherjee-CanDiag (2014)&lt;/value&gt;&lt;recordNumber&gt;604&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;388&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Please see Pancreatic Cancer Reference Set&lt;/value&gt;&lt;recordNumber&gt;605&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;388&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;606&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;388&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application: Surinder Batra- University of Nebraska (2014)&lt;/value&gt;&lt;recordNumber&gt;607&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;389&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Pancreatic Cancer Reference Set&lt;/value&gt;&lt;recordNumber&gt;608&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;389&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;609&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;389&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application: Ivan Blasutig-University of Toronto (2014)&lt;/value&gt;&lt;recordNumber&gt;610&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;392&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Pancreatic Cancer Reference Set&lt;/value&gt;&lt;recordNumber&gt;611&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;392&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;612&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;392&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application: Kazufumi Honda-National Cancer Center (2014)&lt;/value&gt;&lt;recordNumber&gt;613&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;394&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see MSA protocol&lt;/value&gt;&lt;recordNumber&gt;614&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;394&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;615&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;394&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;MSA Bladder Reference Set Application: Charles Rosser-Hawaii (2014)&lt;/value&gt;&lt;recordNumber&gt;616&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;395&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;endometrioid and serous ovarian cancer tissues and plasma.&lt;/value&gt;&lt;recordNumber&gt;617&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;395&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;618&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;395&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set Application: Karen  Abbott -University of Arkansas (2014)&lt;/value&gt;&lt;recordNumber&gt;619&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;396&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;620&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;396&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;621&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;396&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Ruth Etzioni-William Beaumont Hospital (2014)&lt;/value&gt;&lt;recordNumber&gt;622&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;397&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;623&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;397&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;624&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;397&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;GSTP1 Methylation&lt;/value&gt;&lt;recordNumber&gt;625&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;399&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;626&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;399&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;627&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;399&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Lin Univ. of Washington/OPKO (2015)&lt;/value&gt;&lt;recordNumber&gt;628&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;401&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Because this study is focused on breast cancer, only sera derived from breast cancer patients and sex matched controls will be included. 
This study does not exclude any individuals on the basis of race or ethnicity.  Every effort is made to encourage participation by racial and ethnic minorities.  
&lt;/value&gt;&lt;recordNumber&gt;629&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;401&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;630&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;401&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Detection Using NAPPA Tumor Antigen Arrays&lt;/value&gt;&lt;recordNumber&gt;631&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;402&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BBD protocol&lt;/value&gt;&lt;recordNumber&gt;632&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;402&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;633&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;402&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BBD Reference Set Application: Jeffery Marks-Duke (2015)&lt;/value&gt;&lt;recordNumber&gt;634&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;403&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;635&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;403&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;636&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;403&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Chris Li-FHCRC (2015)&lt;/value&gt;&lt;recordNumber&gt;637&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;404&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;638&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;404&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;639&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;404&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Nashville Early Diagnosis Lung Cancer Project&lt;/value&gt;&lt;recordNumber&gt;640&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;405&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;641&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;405&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The overall objective is to validate serum protein markers for early diagnosis of ovarian cancer with the ultimate goal being to develop a multiparametric panel consisting of 2-4 novel markers with 10 known markers for phase 3 analysis. In phase 1, we will screen for markers able to pass a threshold of 98% specificity and 30% sensitivity in a cohort of 300 women.  Markers that pass phase 1 validation will be investigated in a phase 2 PRoBE cohort with a 98% specificity and 70% sensitivity cut-off. Finally, markers that pass phase 2 validation will be evaluated in EDRN CVC laboratory specimens with a cut-off of &amp;#062; 98% specificity and 90% sensitivity.&lt;/value&gt;&lt;recordNumber&gt;642&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;405&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Intergrated Systems Biology Approach for Ovarian Cancer Biomarker Discovery&lt;/value&gt;&lt;recordNumber&gt;643&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;410&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;N/A.&lt;/value&gt;&lt;recordNumber&gt;644&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;410&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Provide measurement assurance for miRNA profiling studies&lt;/value&gt;&lt;recordNumber&gt;645&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;410&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of reference samples and interlaboratory testing to improve the confidence in the measurement of microRNAs&lt;/value&gt;&lt;recordNumber&gt;646&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;411&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;647&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;411&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;648&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;411&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Thompson UT Health Science Center San Antonio (2014) SNPs for PCa Outcome&lt;/value&gt;&lt;recordNumber&gt;649&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;412&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;650&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;412&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;651&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;412&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Nelson Fred Hutchinson Cancer Research Center (2013) Telomere Length in men with Prostate Cancer under Active Surveillance&lt;/value&gt;&lt;recordNumber&gt;652&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;413&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;653&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;413&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;654&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;413&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Lin Univ. of Washington/OncoChip (2013)&lt;/value&gt;&lt;recordNumber&gt;655&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;414&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;656&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;414&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;657&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;414&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PASS Reference Set Application: Carroll Univ. of California SF (2012) PC101769 Predicting Prostate Cancer Progression at Time of Diagnosis&lt;/value&gt;&lt;recordNumber&gt;658&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;415&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see DCP&lt;/value&gt;&lt;recordNumber&gt;659&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;415&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;660&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;415&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Hemken - Abbott (2015)&lt;/value&gt;&lt;recordNumber&gt;661&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;416&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;662&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;416&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;663&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;416&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prevalidation for Rectal PWS for Colon Cancer Screening&lt;/value&gt;&lt;recordNumber&gt;664&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;417&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;665&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;417&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;666&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;417&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers for Early Detection of Clinically Relvant Prostate Cancer: A Multi-Institutional Validation Trial - Genomic Health, Inc.&lt;/value&gt;&lt;recordNumber&gt;667&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;419&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;668&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;419&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;669&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;419&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PCA3 Reference Set Application: Samantha Maragh NIST&lt;/value&gt;&lt;recordNumber&gt;670&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;420&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;671&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;420&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;672&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;420&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Novel approaches to study immune responses to post translational modifications for cancer detection&lt;/value&gt;&lt;recordNumber&gt;673&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;421&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The samples will be assembled from the existing stocks in the biorepositories under the direction of Dr. Brand at UPMC and Dr. Maitra at MDACC (including his consortium sites at the University of Utah and Indiana University; these latter sites are particularly germane to control samples from benign pancreatic diseases as well as long standing diabetes samples). Each site will select sample from approximately 50 cases and 50 controls, for a total of around 100 cases and 100 controls. Approximately 5 mL plasma from each patient will be available for combined evaluation of multiple markers from team study. The total volume requirement to complete our aims is only about 1 mL, but we will set aside extra sample for repeats and for subsequent testing with additional emerging biomarkers. The cases will be patients with resectable PDAC, with stage I or II disease, and the controls will be primarily patients with a benign condition of the pancreas and some people with no pancreatic abnormalities. Patients with no history of pancreatic disease and normal pancreatic tests and deemed to have normal pancreata are considered to be healthy (HC). Patients having history of benign pathologies are categorized into the benign (BC) group. PDAC staging has been determined surgically, based on operative pathology or biopsy of metastatic disease, or clinically, based on radiographic imaging studies. Grade, location of the tumor, stage, smoking status, history of type II diabetes, and alcohol use will be based on the review of hospital records. 

The PDAC patients will be primarily those with adenocarcinoma, because that is the predominant type, but we will include some neuroendocrine, ampullary, and other rarer types in order to cover the range of pancreatic malignancies encountered in practice. We are aiming to identify 30-40 cases in the existing biorepository that were enrolled within three years of diagnosis of type-2 diabetes. To provide a matched control group, we will seek to ide&lt;/value&gt;&lt;recordNumber&gt;674&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;421&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The gastrointestinal collaborative group within the EDRN is in an optimal position to carry out such a study given its shared resources and interactive structure. In this project, the two pancreatic CVCs in the EDRN will provide samples to be distributed to four laboratories with promising biomarkers. The laboratories will run their own assays and perform initial analyses on the blinded PDAC and control samples. Our biostatistical collaborator, Dr. Huang at FHCRC, will perform the statistical evaluations. Biomarkers meeting the predetermined performance criteria will move forward to further validation using the EDRN reference set. In addition, we will determine whether any novel combinations of biomarkers should be further tested.&lt;/value&gt;&lt;recordNumber&gt;675&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;421&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;A Biomarker  Bakeoff in Early Stage Pancreatic Cancer&lt;/value&gt;&lt;recordNumber&gt;676&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;422&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;677&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;422&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;678&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;422&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set A Application: Pierre Massion-Vanderbilt (2017)&lt;/value&gt;&lt;recordNumber&gt;679&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;423&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;680&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;423&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;681&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;423&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application: Samir Hanash-MD Anderson (2017)&lt;/value&gt;&lt;recordNumber&gt;682&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;424&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Patients enrolled in PASS will be included in this study. PASS Inclusion criteria include:
   1. Histologically-confirmed adenocarcinoma of the prostate.
   2. Elected Active Surveillance as a management plan for prostate cancer.
   3. Clinically localized prostate cancer: cT1-2, NX or N0, MX or M0.
   4. No previous treatment for prostate cancer, including hormonal therapy, radiation therapy, surgery, chemotherapy.
   5. Minimum of 10 core biopsy if diagnosed within a year prior to study entry or 2 biopsies, one within the past 2 years, if diagnosed more than a year prior to study entry.
   6. Consent to use of specimens for research on prostate cancer.

Exclusion criteria:
   1. Primary Gleason pattern 4 prior to urine specimen collection.
   2. &amp;#8805;34% of biopsy cores containing cancer at a biopsy prior to urine specimen collection.
   3. Study entry &amp;#062; 18 mo after diagnosis.
   4. 1 or more biopsy after diagnosis and before first urine specimen collection.
   5. First surveillance biopsy &amp;#062; 2 ½ years after diagnosis.
&lt;/value&gt;&lt;recordNumber&gt;683&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;424&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;684&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;424&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Evaluating SelectMDx for the prediction of high-grade prostate cancer in men with low-grade prostate cancer on active surveillance in the Canary Prostate Active Surveillance Study (PASS)&lt;/value&gt;&lt;recordNumber&gt;685&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;425&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;686&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;425&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;687&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;425&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Radiomic Imaging Features and Epidemiology of Incidental Pulmonary Nodules&lt;/value&gt;&lt;recordNumber&gt;688&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;426&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;689&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;426&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;690&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;426&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Expansion of Enduring Infrastructure to Support Lung Cancer Screening Research&lt;/value&gt;&lt;recordNumber&gt;691&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;427&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;692&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;427&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;693&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;427&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: A Phase 2 Biomarker Study&lt;/value&gt;&lt;recordNumber&gt;694&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;428&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;695&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;428&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;With the rapid utilization and ongoing advancements in cross-sectional abdominal imaging, the detection of pancreatic cysts has become increasingly frequent. It is reported pancreatic cysts are identified in 1.2- 2.6% of abdominal computed tomography (CT) scans. Many of these cysts, including serous cystadenomas (SCA) and pseudocysts, are benign and can be monitored clinically. In contrast, mucinous cysts, which include intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), have the potential to progress to pancreatic adenocarcinoma (PDAC). Currently, a multidisciplinary approach is recommended in the assessment of pancreatic cysts. This includes clinical and radiographic evaluation, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), cytology, cyst fluid analysis (e.g., viscosity) and tumor markers (e.g., carcinoembryonic antigen (CEA)). Despite a combination of methodologies, the distinction between mucinous cysts from other pancreatic cysts can be difficult. Moreover, the detection of PDAC within a pancreatic cyst can be even more challenging. Thus, there is a dire need for diagnostic tests that can accurately differentiate mucinous from non-mucinous pancreatic cysts and the presence versus absence of advanced neoplasia within a pancreatic cyst. This proposal represents the formation of a multiinstitutional team investigators under the collective name of the Pancreatic Cyst Biomarker Alliance (PCBA) and will validate seven promising pancreatic cyst fluid biomarkers. These biomarkers include targeted DNA somatic and epigenetic alterations, elevations in protein expression, increased protein enzymatic activity and decreasing metabolites that can be easily assayed using minimal amounts of aspirated pancreatic cyst fluid. Within a two-year timeframe, the PCBA will blindly evaluate over 200 pancreatic cyst specimens per assay to establish their future clinical utility. Moreover, these biomarkers will be correlated with known clinicopathologic variables relevant to pancreatic cysts and cross-validated with other assays. Upon completion of this study, the PCBA will have identified and optimized pancreatic cyst fluid biomarkers for future prospective clinical trials.&lt;/value&gt;&lt;recordNumber&gt;696&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;428&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Cyst Biomarker Validation Study&lt;/value&gt;&lt;recordNumber&gt;697&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;429&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;698&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;429&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;699&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;429&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of biomarkers for ER+ breast cancer&lt;/value&gt;&lt;recordNumber&gt;700&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;430&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;TBD&lt;/value&gt;&lt;recordNumber&gt;701&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;430&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;702&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;430&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate-MRI&lt;/value&gt;&lt;recordNumber&gt;703&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;431&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;704&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;431&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;705&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;431&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Jendoubi-Milagen (2017)&lt;/value&gt;&lt;recordNumber&gt;706&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;433&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The study population is derived from a collaboration across &amp;#062;50 sites. All subjects have been diagnosed with very low-risk, low-risk, or low volume intermediate-risk PC and have elected AS. All have been consented for genetic studies and enrolled in this IRB-approved study. AS success will be defined as having undergone AS for at least 3 years without evidence of tumor progression or misclassification&lt;/value&gt;&lt;recordNumber&gt;707&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;433&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;708&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;433&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Germline Genetic Variants and Faliure of Acitve Sureveillance&lt;/value&gt;&lt;recordNumber&gt;709&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;434&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;710&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;434&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;711&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;434&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort&lt;/value&gt;&lt;recordNumber&gt;712&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;435&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;713&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;435&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;714&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;435&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of Novel Cancer Biomarkers in Serum and Urine Specimens&lt;/value&gt;&lt;recordNumber&gt;715&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;436&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;716&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;436&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;717&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;436&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of Breast Cancer Biomarkers Using DNA and Protein Microarray Technologies&lt;/value&gt;&lt;recordNumber&gt;718&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;437&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;719&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;437&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;720&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;437&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Evaluation of tissue biomarker of Urologic cancer, including prostate, bladder and kidneys using surplus human tissues&lt;/value&gt;&lt;recordNumber&gt;721&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;438&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;722&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;438&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;723&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;438&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Characterization of SPINK1 in Prostate Cancer (A sub-study of a single biomarker)&lt;/value&gt;&lt;recordNumber&gt;724&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;439&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;725&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;439&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;726&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;439&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pre-validation of TMPRSS2:ERG+PCA3 risk models for men on active surveillance&lt;/value&gt;&lt;recordNumber&gt;727&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;440&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;728&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;440&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;729&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;440&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Discovery of Novel Gene Elements Associated with Prostate Cancer Progression&lt;/value&gt;&lt;recordNumber&gt;730&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;441&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;731&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;441&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;732&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;441&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Tumor Profiling through High-throughput Sequencing&lt;/value&gt;&lt;recordNumber&gt;733&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;442&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;734&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;442&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;735&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;442&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Biopsy Clinical Database/Tissue Bank IRBMED# 2004-0442&lt;/value&gt;&lt;recordNumber&gt;736&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;443&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;737&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;443&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;738&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;443&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Profiling of Cancer: Identification and Characterization of Candidate Biomarkers and Regulatory Genes. IRBMED # 2001-0155&lt;/value&gt;&lt;recordNumber&gt;739&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;444&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;740&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;444&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;741&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;444&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development and Validation of Tissue Microarray Technology to Evaluate Molecular Alterations in Cancer. IRBMED# 2000-0108&lt;/value&gt;&lt;recordNumber&gt;742&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;445&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;We propose to analyze plasma at time of diagnosis as well as the subsequent 4 semiannual plasma specimens, thus allowing for analysis of 5 specimens spaced evenly over 2.5 years of follow-up for those patients who do not reach the endpoint before this time. This will allow analysis not only of miRNA markers at baseline but also over time. It may well be the case that a single assessment may not predict outcomes of AS years down the road, but that a change in miRNA profile may presage these outcomes via a non-invasive assay.
For this pilot study, we request 500 samples to establish the baseline miRNA expression in plasma at study entry. Inclusion criteria would be 100 PASS participants with no treatment within six months of diagnosis, enrolled within 5 years of diagnosis, and have an on-study surveillance biopsy. Early enrollees regardless of time on AS, and include both those with evidence of progression and those without evidence of progression.  We request up to 5 serial specimens over time per patient. Plasma samples ideally will have less than 2 freeze-thaw cycles; please note the number if this is exceeded. We also request 50 randomly selected, matched urine samples to pilot.
We propose to compare men with clear progression to those with clear non-progression. We will define clear progression by an increase in overall risk as reflected by CAPRA &amp;#8805;4, which requires either development of bGS 4+3 disease or bGS 3+4 together with a combination of high PSA and/or tumor volume. Clear non-progression will be defined as maintaining strict criteria for surveillance (clinical stage &amp;#8804;T2aN0M0, bGS &amp;#8804;3+3, PSA &amp;#060;10 ng/ml, &amp;#8804;33% of biopsy cores positive, &amp;#8804;50% tumor involvement in any one core9) for at least 3 years of observation.
&lt;/value&gt;&lt;recordNumber&gt;743&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;445&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;744&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;445&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment&lt;/value&gt;&lt;recordNumber&gt;745&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;446&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;746&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;446&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;747&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;446&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set-Rapid-Application: Nilsson Glycobond (2018)&lt;/value&gt;&lt;recordNumber&gt;748&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;447&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Case Inclusion: females (18 or older) with unilateral breast cancer with no prior history of breast cancer and images must be before treatment
Case Exclusion: bilateral breast cancer patients, or patients with a history of breast cancer and/or treatment before mammogram
Control Inclusion: females (18 and older) with no prior breast cancer and must be an internal (Moffitt) patient
Control Exclusion: history of breast cancer or external (non-Moffitt) patient
&lt;/value&gt;&lt;recordNumber&gt;749&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;447&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;750&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;447&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;An Automated System for Breast Cancer Biomarker Analysis&lt;/value&gt;&lt;recordNumber&gt;751&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;448&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Case Inclusion: females (18 or older) with unilateral breast cancer with no prior history of breast cancer and images must be before treatment
Case Exclusion: bilateral breast cancer patients, or patients with a history of breast cancer and/or treatment before mammogram
Control Inclusion: females (18 and older) with no prior breast cancer and must be an internal (Moffitt) patient
Control Exclusion: history of breast cancer or external (non-Moffitt) patient
&lt;/value&gt;&lt;recordNumber&gt;752&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;448&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Mammographic breast density (BD) is a significant breast cancer risk factor, second in magnitude only to inherited BRCA mutations. Most research studies generating this conclusion used an operator-assisted method (applied to digitized film) to estimate the percentage of BD (i.e. PD, the standard), which requires an expert technician to outline the breast region and define thresholds. Although clearly an invaluable research tool, this standard does not lend itself to automation, and is therefore not amenable for application in the clinical setting (i.e. large-scale implementation) for patient risk assessment and management. Our goal is to lay the foundation for translating the demonstrated research value of BD into the clinic by advancing our recent achievements in full field digital mammography (FFDM), the emerging standard modality for breast screening in the US. We developed a calibration system for FFDM using a specific unit that produced four significant findings: (1) a standardization technique that makes pixel values comparable across all images, (2) a new calibrated spatial variation BD measurement (or Vc) that offered a stronger measurement of risk than the standard, (3) Vc is a function of PD, another calibrated measure of BD that is also a significant risk factor, and other important risk covariates, i.e. high correlation but non-linear, and (4) demonstrated the variation measure (or V) applied to raw mammograms (or Vr) is also a significant breast cancer risk factor. In this proposed work we build on our calibration approach and apply it to different FFDM units. We will validate the Vc and Vr measures from different FFDM technology and make comparisons with our previous findings using a matched case-control study using both pre-existing and new FFDM datasets. Because differences in detector designs have the potential to alter spatial variation, it is imperative to assess these influences on the new V-metrics to demonstrate that breast cancer risk is not dependent upon the system design. We will quantify the gains derived from calibration by comparing Vc and Vr, because gains are derived at the expense of advanced image processing and analyses. We will determine the optimal breast density measure and representation (i.e. is calibration required), where optimal is defined by these attributes: automated, quantitative, reproducible, consistent across different imaging platforms, and offers risk prediction at least equivalent with that offered by PD. To meet our objectives, we use accepted techniques and introduce novel analysis strategies that include statistical learning to better capture the relationships between the import risk covariates. This work will provide a prescription for making the optimal BD measurement. The successful completion of this work will allow the full scale integration of BD into the clinical environment. Potential applications include personalized care of patients in terms of screening frequency, risk reduction interventions, and the identification of situations where mammography may be ineffective (i.e. where dense tissue significantly reduces either sensitivity or specificity of mammography).

&lt;/value&gt;&lt;recordNumber&gt;753&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;448&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Automated Quantitative Measures of Breast Density&lt;/value&gt;&lt;recordNumber&gt;754&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;449&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Case Inclusion: females (18 or older) with unilateral breast cancer with no prior history of breast cancer and images must be before treatment
Case Exclusion: bilateral breast cancer patients, or patients with a history of breast cancer and/or treatment before mammogram 
Control Inclusion: females (18 and older) with no prior breast cancer and must be an internal (Moffitt) patient Control Exclusion: history of breast cancer or external (non-Moffitt) patient.
&lt;/value&gt;&lt;recordNumber&gt;755&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;449&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;We propose to establish the Moffitt Imaging Biomarker Validation Center (MIBVAC) for the EDRN based on the following backgrounds, expertise, resources, biomarker validation studies, and a network collaboration plan. 
Significance of Imaging for Early Detection of Cancer. The goals of early detection and risk assessment research are to develop non-invasive methods to (i) accurately detect and characterize cancers at their earliest stages, and (ii) predict future disease risk and occurrence. For breast imaging, breast density is a significant breast cancer risk factor as measured and validated with film and full field digital mammography (FFDM). Breast density is not routinely incorporated into clinical risk assessment due to difficulties in obtaining automated, accurate, and reproducible measurements. Mammography is currently advancing from FFDM to digital breast tomosynthesis (DBT) screening. Thus, there is a critical need to translate and validate breast density from conventional mammography to DBT for more accurate risk assessment at the individual level, thereby enabling clinical intervention. 
&lt;/value&gt;&lt;recordNumber&gt;756&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;449&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Moffitt Imaging Biomarker Validation Center&lt;/value&gt;&lt;recordNumber&gt;757&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;450&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The samples will be assembled from the existing stocks in the biorepositories under the direction of Dr. Brand at UPMC and Dr. Maitra at MDACC  Each site will select sample from approximately 50 cases and 50 controls, for a total of around 100 cases and 100 controls. Approximately 5 mL plasma from each patient will be available for combined evaluation of multiple markers from team study. The total volume requirement to complete our aims is only about 1 mL, but we will set aside extra sample for repeats and for subsequent testing with additional emerging biomarkers. The cases will be patients with resectable PDAC, with stage I or II disease, and the controls will be primarily patients with a benign condition of the pancreas and some people with no pancreatic abnormalities. Patients with no history of pancreatic disease and normal pancreatic tests and deemed to have normal pancreata are considered to be healthy (HC). Patients having history of benign pathologies are categorized into the benign (BC) group. PDAC staging has been determined surgically, based on operative pathology or biopsy of metastatic disease, or clinically, based on radiographic imaging studies. Grade, location of the tumor, stage, smoking status, history of type II diabetes, and alcohol use will be based on the review of hospital records. &lt;/value&gt;&lt;recordNumber&gt;758&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;450&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The GI collaborative team project from the previous year had the goal of performing a rigorous evaluation of multiple candidate biomarkers using a common sample set. A secondary goal was to develop novel combinations of cross-lab biomarkers that should be tested further. The project met its goals: a blinded, 182- sample set made up of samples from MD Anderson and UPMC was distributed to the four sites running candidate biomarkers; each site ran its assays and made calls; and Dr. Huang and the FHCRC performed the statistical analyses. Several of the biomarkers and novel combinations showed promise and warrant further testing. 

We plan to build on this progress in the new team project. The previous study gave excellent information about which markers should move forward to further validation, and which combinations should be further explored. The study also revealed where assays need to be improved or optimized, and what types of samples should be included in future test sets. 

For biomarkers that met performance criteria—that showed improvement over CA19-9—we will perform further validation without alteration to the biomarker. For biomarkers that showed good potential but need improvement in certain areas, we will seek to optimize or improve performance and then retest their performance. Finally, for any novel combination-markers, including panels using markers from separate labs (for example, circulating cell free DNA), we will perform validation tests. 
&lt;/value&gt;&lt;recordNumber&gt;759&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;450&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Cancer Bake Off 2&lt;/value&gt;&lt;recordNumber&gt;760&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;452&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;761&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;452&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;762&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;452&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Application: Paulovich (2018)&lt;/value&gt;&lt;recordNumber&gt;763&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;453&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The data sample of the development phase will be a simple random sample from the currently available PASS participants; the remaining PASS participants are reserved for the validation phase. A sufficient number of participants will be sampled such that a total number of 657 biopsies are reached. Upon completion of the development phase, the developed rules will be evaluated and a decision made regarding whether the study will proceed to the validation phase. This decision will be based on whether any of these rules may achieve 35% specificity at the controlled 95% sensitivity level. If so, such rules will be validated. Otherwise, the study will be stopped.&lt;/value&gt;&lt;recordNumber&gt;764&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;453&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;765&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;453&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prediction rules for aggressive prostate cancer in AS population&lt;/value&gt;&lt;recordNumber&gt;766&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;454&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;767&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;454&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;768&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;454&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Application:Sumio Ohtsuki/Kazfumi Honda-Kumamoto University (2019)&lt;/value&gt;&lt;recordNumber&gt;769&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;455&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;770&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;455&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;771&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;455&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prediction Rules Combining PHI with Urinary RNA Testing for Aggressive Prostate Cancer Detection&lt;/value&gt;&lt;recordNumber&gt;772&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;456&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;773&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;456&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;774&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;456&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas Great Lakes New England (GLNE) Clinical Validation Center&lt;/value&gt;&lt;recordNumber&gt;775&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;457&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;776&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;457&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;777&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;457&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Cancer Reference Set Application (Rapid): Chilkoti (2019)&lt;/value&gt;&lt;recordNumber&gt;778&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;458&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;779&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;458&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;780&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;458&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Evaluating DNA Damage and DNA Repair Capacity as Biomarkers of Non- Indolent Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;781&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;459&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;782&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;459&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;783&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;459&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Evaluation of emerging tissue-based biomarkers for aggressive prostate cancer in men on active surveillance&lt;/value&gt;&lt;recordNumber&gt;784&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;460&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see PCA3 study&lt;/value&gt;&lt;recordNumber&gt;785&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;460&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;see Objectives&lt;/value&gt;&lt;recordNumber&gt;786&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;460&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PCA-3 Reference Set Application: Zhang/Johns Hopkins: Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer&lt;/value&gt;&lt;recordNumber&gt;787&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;461&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;788&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;461&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;see Objectives&lt;/value&gt;&lt;recordNumber&gt;789&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;461&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of Tissue Microarray Resource for Pancreatic Cancer&lt;/value&gt;&lt;recordNumber&gt;790&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;462&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;791&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;462&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;792&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;462&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Rapid Reference Set Application: Villanueva Mt Sinai-Icahn (2019)&lt;/value&gt;&lt;recordNumber&gt;793&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;463&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;794&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;463&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;795&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;463&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of Digital Microfluid Methylation Assays for the Detection of Early Stage Ovarian Cancer&lt;/value&gt;&lt;recordNumber&gt;796&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;464&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;797&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;464&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;798&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;464&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Upgrading Reference Set (URS) Application: Paul Boutros-UCLA (2020)&lt;/value&gt;&lt;recordNumber&gt;799&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;467&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Detailed information about the cohort size and composition are not provided here in order to keep the investigators blinded, but that information is provided separately in a support letter from Drs. Feng and Huang. They have reviewed and approved the composition of this set. Samples derived from PAGER study and PluSS study.&lt;/value&gt;&lt;recordNumber&gt;800&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;467&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;&lt;recordNumber&gt;801&lt;/recordNumber&gt;&lt;numberOfRecords&gt;801&lt;/numberOfRecords&gt;&lt;ontologyVersion&gt;1.8&lt;/ontologyVersion&gt;&lt;Identifier&gt;467&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pre-diangtic Pancreatic Cancer Set Aside Project&lt;/value&gt;</Protocol_or_StudyResult></Protocol_or_StudyResponse></soap:Body></soap:Envelope>